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Abstract 
  
    
 
Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide 
ligands of these receptors display biased agonism and this may provide future therapeutic 
advantage. Recent active structures of the calcitonin (CT) and glucagon-like peptide-1 (GLP-1) 
receptors reveal distinct engagement of peptides with extracellular loops (ECLs) 2 and 3, and 
mutagenesis of the GLP-1R has implicated these loops in dynamics of receptor activation. In the 
current study, we have mutated ECLs 2 and 3 of the human CT receptor (CTR), to interrogate 
receptor expression, peptide affinity and efficacy. Integration of these data with insights from the 
CTR and GLP-1R active structures, revealed marked diversity in mechanisms of peptide 
engagement and receptor activation between the CTR and GLP-1R. While the CTR ECL2 played a 
key role in conformational propagation linked to Gs/cAMP signalling this was mechanistically 
distinct from that of GLP-1R ECL2. Moreover, ECL3 was a hotspot for distinct ligand- and 
pathway- specific effects, and this has implications for the future design of biased agonists of class 
B GPCRs.  
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1. Introduction 
Class B1 G protein-coupled receptors (GPCRs) are the targets for peptide hormones that play major 
roles in the development and maintenance of lymphatic and cardiovascular function, bone 
homeostasis, metabolic regulation, migraine, stress and anxiety
1
. Consequently, these receptors are 
important therapeutic targets.  
 
The calcitonin (CT), Class B1 GPCRs (CTRs), are highly expressed on osteoclasts and have been 
exploited therapeutically for treatment of bone disorders, including Paget’s disease, hypercalcemia 
of malignancy and osteoporosis
2-5
. The receptors are also expressed in numerous other cells and 
tissues including leucocytes and their precursors, the central nervous system, kidney, lung, 
gastrointestinal tract and reproductive tissues
6
, thereby influencing pain perception, feeding and 
reproduction, and ion secretion
2,7
, though these actions are not well understood. Furthermore, CTRs 
can interact with the receptor activity modifying protein (RAMP) family to form high affinity 
receptors for amylin (Amy) and calcitonin gene-related peptide (CGRP)
8
.  
 
CT peptides from different species have been identified and can be classified into 3 major 
subgroups based on evolution and sequence conservation: human/rodent, artiodactyl (e.g., porcine) 
and teleost (salmon/eel)/chicken. Both human and salmon CT have been approved for treatment of 
bone disorders including Paget’s disease and osteoporosis, however, they have distinct binding 
kinetics, affinity and efficacy
9-11
 that impact on G protein recruitment and activation
11
, suggesting 
different modes of interaction with CTRs. 
 
Orthosteric peptide ligands of Class B1 GPCRs are proposed to interact with their cognate receptors 
via a two-domain mechanism, with an initial engagement of the C-terminus of the peptide with the 
N-terminal extracellular domain (ECD) of the receptor that allows the peptide N-terminus to bind to 
the transmembrane (TM) spanning receptor core comprising the 7 TM helices and 3 interconnecting 
  
    
 
extracellular loops (ECLs), leading to receptor activation
12
. This mode of binding is supported by 
recent full-length, active, Gs-complexed structures of the CTR
13
 (bound to sCT) and glucagon-like 
peptide-1 (GLP-1) receptor (GLP-1R) (bound to GLP-1
14
, or exendin-P5
15
). Nonetheless, there 
were marked differences in the orientation of the receptor ECD relative to the receptor core and 
correlative changes in presentation of the peptides to the receptor core, linked to differences in the 
degree of secondary structure of the peptides
13-15
. Moreover, the CT-family peptides have a cyclic, 
cysteine-disulfide linked N-terminus between amino acids 1 and 7 (2 and 7 for Amy and CGRP) 
that contrasts with the extended helix of GLP-1, and alters the relative interaction of the peptide N-
termini with the ECLs and proximal TM helix segments. 
 
Mutagenesis and crosslinking studies have shown that the ECLs of Class B1 GPCRs are critical for 
both peptide binding and propagation of conformational change associated with receptor 
activation
14-20
. For the GLP-1R, alanine-scanning mutagenesis revealed that the ECLs, particularly 
ECL2 and ECL3, were also important in the biased agonism of peptides, but had distinct 
contribution to pathway specific signalling
16,21
. For this receptor, both ECL2 and ECL3 played a 
critical role in cAMP formation, and intracellular calcium (iCa
2+
) mobilisation, while effects on 
ERK phosphorylation (pERK) were principally confined to residues within ECL3.  
 
In the current study, we have performed alanine-scanning mutagenesis of amino acids in ECLs 2 
and 3 of the hCTR and interrogated mutant receptors for their effects on cell surface receptor 
expression, peptide affinity and efficacy for cAMP and IP1 accumulation, as well as pERK in 
response to calcitonin (sCT, hCT, pCT) and related family (Amy, CGRP) peptides. This work 
revealed both differences in how the receptor engages with and is activated by the different CT-
family peptides, and in the role of ECLs 2 and 3 between the CTR and GLP-1R. 
 
2. Materials and Methods 
  
    
 
2.1 Reagents  
All peptides were purchased from Mimotopes. Dulbecco’s Modified Eagle’s Medium (DMEM) was 
purchased from Invitrogen. Foetal bovine serum (FBS) was purchased from Thermo Electron 
Corporation. AlphaScreen reagents, Lance cAMP kit, 384-well Optiplates were purchased from 
PerkinElmer. SureFire
TM
 ERK1/2 reagents were obtained from TGR Biosciences and PerkinElmer. 
IP-One HTRF® assay kit was from CisBio. Antibodies were purchased from R&D systems and 
ThermoFisher. All other reagents were purchased from Sigma-Aldrich or BDH Merck and were of 
an analytical grade. 
 
2.2 Mutagenesis    
Desired mutations were introduced to N-terminally c-Myc tagged human CTR in pENTER11 
(Invitrogen) via the Q5® High-Fidelity PCR Kit (New England Biolabs), then LR recombination 
reactions were conducted to transfer mutated and wild-type (WT) receptor into the pEF5/FRT/V5-
DEST destination vector using Gateway Technology (Invitrogen). The oligonucleotides for 
mutagenesis were purchased from Gene-Works (Thebarton, SA, Australia) and mutants were 
confirmed by automated-sequencing.  
 
2.3. Stable cell line generation and cell culture  
The mutant or wild-type (WT) receptor genes were integrated into FlpIn-CV1 cells using Flp-InTM 
system (Invitrogen). Stable Flp-In expression cell lines were generated through polyclonal 
selection, screening and maintained in Dulbecco’s modified Eagle’s medium supplemented with 5% 
 (Invitrogen) at 37°C in 5% CO2.  
 
2.4 Homologous whole cell competition binding assay 
Homologous radioligand competition was performed on 2.5x10
4 cells well seeded into   -well trays 
and cultured o ernight   ells were incubated o ernight at    C with two concentrations of 125I-
  
    
 
sCT(8-32) (between 25 and 100 pM; specific activity, 2000 Ci/mmol
9
) and serial dilutions of non-
iodinated sCT(8-32) . Non-bound ligand was removed and bound ligand activity was measured 
using a γ counter (Wallac Wizard 1 70 Gamma  ounter, Perkin Elmer, 80% counter efficiency)  
Values were normalised against non-specific binding (0%) defined by the presence of 1 μM of 
unlabelled sCT(8-32), and total ligand bound in absence of competing sCT(8-32) (100%). 
 
2.5 Heterologous whole cell competition binding assay  
Competition binding was performed as previously described
41
 on whole cells in 96-well plates by 
using the antagonist radioligand 
125
I-sCT(8-32) (~0.1 nM), and competing with increasing 
concentrations of unlabelled peptide. Non-specific binding was defined by co-incubation with 1 μM 
unlabelled sCT(8-32). Following overnight incubation non-bound ligand was removed and 
radioactivity was determined using a gamma counter.  
 
2.6 Cell surface expression by FACS  
Surface expression of c-Myc tagged CTR mutants stably expressed in CV-1 cells was quantified by 
flow cytometry using standard methods. Cells were plated into 6 well trays at approximately 5x 10
5
 
cells per well the day before assay. Cells were harvested using versene. All staining steps were 
conducted in ice cold HBSS with 0.1% BSA and 20 mM HEPES (pH 7.4). Blocking was conducted 
in 5% BSA.  Primary antibody staining was performed with a mixture of 5 µg/mL 9E10 (anti-c-
Myc) and 1 µg/mL Mab4614 (anti-CTR, R&D Systems). The secondary antibody was 1 µg/mL 
goat anti-mouse AF647 (ThermoFisher). Sytox blue was used for live/dead discrimination. Data 
were collected on a FACS CantoII (BD Biosciences) with at least 20,000 live cells collected per 
sample, WT stained CTR sample and stained parental CV-1 cells were collected at the beginning 
and the end of each run. Data were analysed using FlowJo. The mean AF647 fluorescence intensity 
from each sample for a particular experiment was normalized against parental (0%) and CTR WT 
(100%) controls. 
  
    
 
 
2.7 cAMP accumulation  
Cells (2.5x10
4
 cells/well) were seeded into 96-well plates and incubated overnight. Cells were 
stimulated with increasing concentrations of ligands for 30 min in the presence of IBMX. The liquid 
was discarded, changed to absolute ethanol and volatilized to dryness at room temperature. Samples 
were then lysed and intracellular cAMP was detected using PerkinElmer Lance kit as previously 
described
16  Data were normalized to the response of 100 μM forskolin   
 
2.8 IP1 accumulation  
Cells (2.5x10
4
 cells/well) were plated into 96 well trays and cultured overnight. Cells were 
stimulated with increasing concentration of ligands for 60 min in the presence of LiCl. Samples 
were lysed and endogenous IP1 was measured using an IP-One HTRF® assay kit (CisBio) as 
specified by the manufacturer  Data were normalised to the maximal response elicited by 100 μM of 
ATP. 
 
2.9 ERK1/2 phosphorylation  
Cells (2.5x10
4
 cells/well) were seeded into 96-well culture plates and incubated overnight. Initially, 
pERK1/2 time-course experiments were performed over 30 min to identify the time point when the 
pERK1/2 response is maximal (6-8 min). Subsequently, this time point was selected to generate 
concentration response for different agonists with ligand addition performed after overnight serum 
starvation. pERK1/2 was detected using an Alphascreen assay as previously described
22
. Data were 
normalized to the maximal response elicited by 10% FBS determined at 6 min.  
 
2.10 Data analysis  
IC50 and Bmax values were estimated from competitive inhibition of 
125
I-sCT(8-32) binding using a 
3-parameter logistic equation (log(inhibitor versus response)) in Prism (v7; Graphpad). Data were 
  
    
 
corrected for radioligand occupancy using the Cheng-Prusoff equation in Prism; as such data are 
reported as pKi. Emax and EC50 were estimated from concentration-response curves using with a 3-
parameter logistic equation in Prism (v7). These values are a composite of functional affinity, 
efficacy and stimulus response coupling. The Black and Leff operational model of agonism
23
 was 
applied to separate effects on pathway-
functional affinity (pKA
cell surface expression to provide a c) that is independent of affinity and 
altered cell surface receptor expression
16
. pKi, pKA 
statistically compared to those of the WT receptor using a one-way analysis of variance (ANOVA) 
and Dunnett’s post- test. Significance was accepted at P< 0.05.  
 
2.11 Molecular modelling and mapping of mutational effects  
The structures of the CTR:CT complexes were generated from the cryo-electron microscopy 
structure of the calcitonin receptor
13
 and the X-ray structure of the CTR ECD
24
. Missing loops were 
generated using Modeller
25
 (1000 structures) and the final loop selected to ensure that the conserved 
residues faced inwards
26
 by analysis of the correlation of the conservation, as measured using the 
Shannon entropy, and the extent to which a residue is buried
27
. 
 
2.12 Molecular dynamics simulations  
CTR:sCT and CTR:hCT complexes were prepared for molecular dynamics simulations by means of 
a multistep procedure that integrates both python htmd
28
 and tcl (Tool Command Language) scripts. 
The pdb2pqr
29
 and propka
30
 software were used to check the protein’s structural integrity and to add 
hydrogen atoms (configurations of titratable amino acid side chains were visually inspected) 
appropriate for a simulated pH of 7.0. The CTR was embedded in rectangular matrixes of a 1-
palmitoyl-2-oleyl-sn-glycerol-3-phospho-choline (POPC) bilayer (previously built by using the 
VMD Membrane Builder plugin 1.1; http://www.ks.uiuc.edu/Research/vmd/plugins/membrane) 
  
    
 
through an insertion method
31
: receptors were first oriented according to the CTR coordinates from 
the OPM database
32
, then lipids overlapping the protein were removed and TIP3P water molecules
33
 
were added to the simulation box by means of the VMD Solvate plugin 1.5 
(http://www.ks.uiuc.edu/Research/vmd/plugins/solvate). Charge neutrality was finally reached by 
adding Na
+
/Cl
-
 counter ions to a final concentration of 0.154 M, according to the VMD Autoionize 
plugin 1.3 (http://www.ks.uiuc.edu/Research/vmd/plugins/autoionize). The CHARMM36 force 
field
34
 was used. 
 
2.13 System equilibration and classic MD run settings 
All the following MD simulation stages were performed by using Acemd
35
. Equilibration of the 
four systems was achieved in isothermal-isobaric conditions (NPT) using the Berendsen barostat
36
 
(target pressure 1 atm) and the Langevin thermostat
37
 (target temperature 300 K) with a low 
damping of 1 ps
-1
. A three-stage procedure with an integration time step of 2 fs was performed: in 
the first stage, 2000 conjugate-gradient minimization steps were applied to reduce the clashes 
between protein and lipids. Then, a 10 ns long MD simulation was performed in the NPT ensemble, 
with a positional constraint of 1 kcal mol
-1 
Å
-2 
on protein and lipid phosphorus atoms. During the 
second stage, 30 ns of MD simulation in the NPT ensemble were performed, constraining all 
protein atoms but leaving the POPC residues free to diffuse in the bilayer. In the last equilibration 
stage, positional constraints were reduced by one half and applied only to the protein backbone 
alpha carbons for a further 10 ns of MD simulation.  
 
For each intermolecular complex, a total of 2 s of unbiased MD was performed, divided in one 
replica 1 s long and two replicas 500 ns long. After equilibration, production MD trajectories were 
computed with an integration time step of 4 fs in the canonical ensemble (NVT) at 300 K, using a 
thermostat damping of 0.1 ps
-1
 and the M-SHAKE algorithm
38
 to constrain the bond lengths 
involving hydrogen atoms. The cut off distance for electrostatic interactions was set at 9 Å, with a 
  
    
 
switching function applied beyond 7.5 Å. Long range Coulomb interactions were handled using the 
particle mesh Ewald summation method (PME)
39
 by setting the mesh spacing to 1.0 Å 
 
2.14 Analysis 
Contacts and hydrogen bonds were quantified using VMD
40
. A contact between two residues was 
considered productive if at least two atoms were detected at distances less than 3.5 Å. A distance 
between acceptor and donor atoms of 3 Å and an angle value of 20° were set as the geometrical cut-
off for hydrogen bonds. Equilibrated coordinates and parameters are available from the following 
doi: 10.5526/ERDR-00000075 
 
Data on the effect of ECL2 and ECL3 mutation on GLP-1R-mediated efficacy were mapped onto 
the high resolution 3.3A structure of exendin-P5 in complex with the hGLP-1R and dominant 
negative Gs heterotrimer (PDB=6B3J
15
). Mapping and visualization of the effect of mutation on 
receptor structure was performed using ICM (Molsoft).  
 
3. Results 
To assess the importance of ECL2 and ECL3 in CTR function, we performed alanine-scanning 
mutagenesis of residues within these loops as well as adjacent TMs, and assessed effects on cell 
surface receptor expression, competitive binding affinity and cAMP accumulation, IP1 
accumulation and ERK1/2 phosphorylation (pERK). These pathways are important for 
physiological, CTR-mediated, signalling
2,7
. Responses were evaluated for representatives of the 
major structural/evolutionary clades of CT peptides, specifically, human CT (hCT) and salmon CT 
(sCT) that are both used clinically, as well as porcine CT (pCT) (Figure 1A). We also assessed 
responses to the related peptides Amy and CGRP that bind to and activate the CTR with low 
affinity/potency, but are potent agonists of CTR/RAMP complexed receptors. Global affinity (pKi) 
was determined from competition with the radiolabelled antagonist peptide 
125
I-sCT(8-32), while 
  
    
 
functional affinity (pKA) and efficacy were determined by quantification of concentration-response 
data with the operational model of Black and Leff
23
 that provides independent measures of pKA and 
All experiments were performed in CV-1 FlpIn cells that lack functional CTR and 
RAMP expression, with receptors stably expressed following isogenic recombination. Data are 
mapped onto the active hCTR structure (5UZ7), following modelling of missing side chains and 
sampling by short time-scale MD. 
 
3.1 Receptor expression 
Residues for mutation were selected based on the recent structure of sCT/hCTR/Gs
13
 and comprised 
amino acids I279-I300 (ECL2) and F356-M376 (ECL3) (Figure 1B,C). Cell surface expression was 
determined by anti-c-Myc antibody binding to the c-Myc tag inserted after the receptor signal 
peptide in the N-terminal ECD (Figure 1B), and quantified by FACS. 
 
Most mutants demonstrated equivalent cell surface expression to that of the WT receptor (Figure 
1D; Table 1), however, a subset of mutants, particularly within ECL2, had altered expression. Only 
K370A in ECL3 had no detectable expression. D287A, C289A, W290A, and I300A in ECL2, and 
I371 in ECL3, also had markedly diminished cell surface expression (<20% of WT). R281A, 
N286A, T295A, L297A, Y299A in ECL2 and F356A in ECL3 were expressed at levels between 
20% and ~40% of WT. A smaller but significant attenuation of expression was observed for 
Y284A, R362A and Y374A. In contrast, T280A significantly increased expression and P360A 
strongly augmented cell surface receptor expression (Figure 1D; Table 1). Within ECL2, those 
residues with strongly attenuated expression formed a continuum within the central portion of the 
loop, suggesting that these residues participate in a network that helps to stabilize the apo receptor 
(Figure 1E). 
 
3.2 ECL2 and ECL3 mutants differentially modulate peptide-specific affinity 
  
    
 
Global affinity was determined by competition of 
125
I-sCT(8-32) binding in whole cells by each of 
the peptides. Homologous competition with sCT(8-32) revealed a pKi for the WT receptor of 
9.70±0.05, and a Bmax of 22,900±2,500 sites/cell (Table 1). Overall, there was a good correlation, 
for the mutant receptors relative to WT, between measured Bmax and cell surface expression data 
from antibody binding (Figure 1F), although there was a high error in Bmax estimates, consistent 
with expectations of cold saturation experiments with only two radioligand concentrations. sCT, 
hCT and pCT had pKi values for the WT receptor of 9.87±0.03, 6.72±0.06 and 8.27±0.07, 
respectively (Table 1), consistent with those reported in previous studies
9,10
.   
 
Mutants with very low expression, N286A, D287A, C289A, W290A, I300A, K370A and I371A, 
displayed little or no detectable 
125
I-sCT(8-32) binding, thereby preventing assessment of global 
affinity, whereas all other mutant receptors exhibited a sufficient radioligand binding window to 
determine peptide affinity. Of these, only R281A, L291A and P360A reduced sCT(8-32) affinity, 
whereas T295A increased affinity of this peptide (Table 1, Figure 2; Figure 3). Similarly, there was 
only limited effect on sCT affinity, with reduced affinity for the R281A, P360A and D373A 
mutants, and increased affinity for S292A. Intriguingly, the L291A mutant that had reduced affinity 
for the antagonist and both hCT and pCT, did not alter sCT affinity. Both hCT and pCT were more 
broadly sensitive to mutation, with those affecting pCT common with hCT, including R281A, 
L291A, T295A, L298A, F359A-P363A and Y372A that principally resided either within 5Å of sCT 
in the CTR model, or were involved in the network of amino acids in the core of ECL2 that was 
linked to receptor stability/expression (Table 1, Figures 1 and 2). There was a significant reduction 
in pCT affinity for the Y299A mutant that also trended lower for hCT. Moreover, there was 
selective, significant attenuation of hCT affinity for L297A, L298A, V357A, V358A, D373A and 
M376A (Table 1, Figure 2).  
 
  
    
 
CGRP and Amy displayed no detectable competition with the radioligand at the wildtype or mutant 
receptors within the concentration range assessed (up to 10 μM), confirming pre ious findings that 
these have low affinity for the CTR. 
 
3.3 ECL2 and ECL3 mutants alter functional affinity in a ligand and pathway dependent manner 
Concentration-response data, for cAMP accumulation, in response to each peptide was established 
for WT and mutant receptors (Figure 4, Table 2), IP1 accumulation (Figure 5; Table 3), and 
ERK1/2 phosphorylation (Figure 6; Table 4). Functional affinity for each of the pathways was 
determined by operational fitting of the concentration response data. The effect of mutation on pKA 
for cAMP formation was broadly similar to the derived pKi values (Figure 6), clustering to either 
residues in proximity to the peptide or in the central segment of ECL2 that was important for 
receptor stability and expression (Figure 2, Figure 8). Unlike the competition binding assay, 
estimates of pKA could be derived for at least one of the peptides for all mutants, except K370A that 
was not expressed at the cell surface (Figure 2, Figure 8, Table 5). Of these, N286A had no impact 
on affinity, while D287A, C289A and W290A caused a marked decrease in pKA for cAMP 
formation for all peptides, and these were the only mutations to alter sCT cAMP pKA values. The 
weak IP1 responses for these mutants made interpretation of effect difficult, however they had clear 
differential impact on pERK pKA values. While none of the mutants altered sCT pERK pKA, 
D287A decreased both hCT and pCT functional affinities, and W290A decreased that for pCT (hCT 
was not detectable), and there was a selective loss of pERK functional affinity for hCT at the 
C289A mutant (Figure 2, Figure 8, Table 5). 
 
There were distinct patterns in the effect of mutation on pKA values both across pathways and 
between peptides. sCT functional affinities were the least sensitive to mutation, and in particular, 
mutations in ECL3 had limited impact. This contrasts with hCT and pCT where ECL3 mutations 
  
    
 
had widespread effect with greatest impact on pKA values derived from IP1 and cAMP signalling 
(Figures 2, 8 and 9, Table 5).  
 
The F359A and P360A mutants induced a global decrease in functional affinity for pERK and IP1 
pathways, but had differential effect on cAMP responses. Neither affected sCT, while P360A 
attenuated pKA values for both hCT and pCT, with a selective loss of affinity for hCT observed for 
the F359A mutant (Figures 2, 8 and 9, Table 5). 
 
For sCT, there was a selective decrease in pKA values linked to pERK for the V293A mutant and a 
selective increase for the I300A and F356A mutants, while none of the other mutants altered pERK-
derived pKA values (Table 5). Analysis of IP1 signalling revealed an IP1 specific loss of affinity for 
all 3 peptides at the Y374A mutant, while there was preferential loss of affinity for sCT and hCT 
for the V358A and M367A mutants. For the latter mutant, while there was no significant effect on 
pCT functional affinity linked to IP1 signalling, there was a selective decrease in the pERK linked 
pKA value. There was also a selective decrease in sCT IP1-derived functional affinity for the 
F285A, E294A, T295A, and Y299A mutants. No other mutants altered sCT functional affinities for 
any of the pathways studied (Figures 2, 8 and 9, Table 5). 
 
hCT and pCT displayed intriguing differences in the pattern of mutational effect on pKA values 
derived from analysis of IP1 and pERK responses. For hCT there was only limited effect of 
mutation in ECL3 on pERK-derived pKA values and these were confined to the membrane proximal 
ECL3/TM6 boundary (V358A-R362A) and Y372A that packs up against this region in the WT 
receptor (Figures 2, 8 and 9, Table 5). This segment was also important for pCT pERK-derived 
functional affinity, but additional effect was seen with the M367A-G369A mutants that are involved 
with packing at the top of the extension of TM7, and which are important for IP1-derived functional 
affinity of hCT and pCT, albeit that not all effects reached significance for both peptides (Table 5). 
  
    
 
ECL3 was important for IP1-derived functional affinities for both hCT and pCT, with those 
mutations impacting on pCT also decreasing hCT pKA values, including residues at the ECL3/TM6 
boundary (F356A-R362A), residues in the distal part of ECL3 that are likely important for 
TM7/TM1 packing (D373A, Y374A) as well as residues located in the upper extension of TM7 
(M368A-G369A) (Figures 2, 8 and 9, Table 5). However, the network of residues important for 
hCT pKA values was more extensive for both the TM6/ECL3 boundary (P363A, S364A), and the 
extension of TM7 (M367A). In contrast, ECL2 played only a limited role in pCT functional affinity 
derived from either IP1 or pERK signalling. Only the I279A mutant altered pCT IP1-derived pKA 
values, although no quantifiable response was obtained for the poorly expressed C289A, W290A 
and I300A mutants (Table 5). For pERK functional affinity, only the D287A, W290A and L291A 
mutants attenuated pCT affinity. This central network was also important of hCT pERK-derived 
pKA values, with N288A and C289A also reducing hCT functional affinity. It is likely that the 
R281A mutant additionally attenuates hCT affinity as no quantifiable response was detected, and 
there was a large decrease in cAMP-derived pKA. For hCT functional affinity derived from IP1 
signalling, there was a broader impact of mutation for ECL2 residues that included T280A-V283A, 
residues of the central core and boundary with ECL1 (D287A-S292A), and L297A and L298A 
(Figures 2, 8 and 9, Table 5).  
 
Due to the low affinity of amylin and CGRP for CTR, and poor coupling to IP1 signalling (data not 
shown), no competitive binding data or IP1-derived functional affinity data could be obtained for 
these peptides. pKA values from operational analysis of the cAMP signalling could be derived for 
most mutants, revealing only limited impact on either amylin or CGRP functional affinity. This was 
particularly true for amylin that mirrored the observations for sCT, with ~10-fold loss of affinity for 
the C289A and W290A mutants. No quantifiable response for the D287A and Y372A mutants (that 
had weak reductions in sCT functional affinity) was observed, while all other mutants failed to 
significantly alter affinity (Figure 8; Table 5, Supplementary Figure 6). Although the magnitude of 
  
    
 
effect was also limited for CGRP in this pathway, there were broader effects of mutations, including 
loss of detectable response for D287A, C289A, and W290A, and reduced affinity for L291A, 
T295A, F356A, W361A and M376A. These residues were also important for hCT functional 
affinity at this pathway (Figures 3 and 10; Table 5). 
 
Both amylin and CGRP are only weakly coupled to pERK, and alanine mutation either had no 
effect or attenuated responses such that they there were not quantifiable. Nonetheless, interesting 
differences were observed between the effect on amylin and CGRP signalling. Residues with very 
low expression, including D287A, C289A, W290A and I371A had no detectable response for either 
peptide. Loss of response for both peptides was also seen for the P360A, Y372A and D373A 
mutants, despite similar or greater (P360A) cell surface expression of the receptor. The L291A, and 
Y299A mutants selectively attenuated, and the N286A mutant selectively enhanced, CGRP 
functional affinity. Functional CGRP affinity for T295A was not significantly altered, and not 
determined for amylin due to large error in parameter estimates, despite a measurable response 
(Figures 8 and 10; Table 5). 
 
3.4 ECL2 and ECL3 play distinct roles in pathway specific efficacy 
3.4.1 Calcitonin peptides 
Interestingly, despite detrimental effects on functional affinity, only enhancement of cAMP efficacy 
was observed for any of the CT peptides (Figures 11A and 12A; Table 6). For sCT and hCT, the 
effect of mutation was similar, and confined to ECL2, with the exception of F356A that resides at 
the base of the peptide binding pocket. Enhanced efficacy was seen for both sCT and hCT for 
R281A, D287A, C289A, W290A, T295A and I300A (Figures 11A and 12A; Table 6). These 
mutants also had reduced cell surface expression (Figure 1), indicative of destabilization of the 
receptor in a manner that lowers the barrier to Gs coupling. N286A caused a selective enhancement 
of hCT efficacy, while pCT had both overlapping and distinct effects following receptor mutation. 
  
    
 
In ECL2, the effect of mutation was conserved with the other peptides except that there was no 
change in pCT efficacy with the D287A mutant, and a selective enhancement of efficacy at the 
L297A mutant. Strikingly, ECL3 residues were also important for pCT cAMP efficacy, with 
P360A, R362A, P363A and D373A causing selective enhancement of efficacy (Figures 11A and 
12A; Table 6).  
 
There was only limited impact of mutation on CT-mediated IP1 efficacy (Figure 11B, Figure 12B, 
Table 6). Within ECL2, no quantifiable response was seen with W290A for any of the peptides, 
with C289A for hCT and pCT (but no effect on sCT), and with D287A for sCT and hCT, but an 
enhanced efficacy for pCT with this mutation. The Y299A mutant attenuated efficacy for all 
peptides, while I300A abolished responses to sCT and pCT but not hCT (Table 6). Within ECL3, 
there was no pCT response with the F356A mutant, but this did not alter efficacy for sCT or hCT. 
The I371A mutant significantly enhanced efficacy for all peptides. The P360A mutant selectively 
reduced hCT efficacy, while the Y372A and M376A mutants selectively attenuated efficacy for 
pCT. No other mutants altered peptide-mediated IP1 efficacy (Figure 11B, Figure 12B, Table 6).  
 
Within ECL2, efficacy was attenuated for all peptides at the Y299A mutant and enhanced at the 
H296A and I300A mutants, albeit that the H296A and I300A mutants did not achieve significance 
for hCT or pCT, respectively (Figure 11C, Figure 12C, Table 6). The C289A mutant selectively 
enhanced sCT efficacy, while no quantifiable response was observed for hCT at the R281A and 
W290A mutants, which did not alter sCT or pCT efficacy. Within ECL3, the mutant effects tended 
to be relatively peptide specific, although no measurable response was observed for any peptide at 
the I371A mutant (Figure 11C, Figure 12C, Table 6). sCT efficacy was least impacted with loss of 
efficacy at the Y372A mutant (that was also seen with hCT and pCT), and selective enhancement of 
efficacy at the F359A, this latter effect contrasted with the enhanced efficacy seen for hCT and 
pCT. The P360A and M376A mutants attenuated pCT and hCT efficacy, albeit that the M376A 
  
    
 
mutant did not achieve significance for hCT. The K366A mutant selectively enhanced hCT 
efficacy, while there was a selective loss of pCT efficacy with the D373A mutant, and selective 
enhancement of efficacy for the M367A and L368A mutants with this peptide (Figure 11C, Figure 
12C, Table 6).  
 
3.4.2 Amylin and CGRP 
Within ECL2 there was no quantifiable response for D287A for either amylin or CGRP, and no 
measurable response to CGRP at the C289A and W290A mutants, while the C289A mutant, along 
with N286A, had enhanced amylin efficacy (Figure 11A, Figure 12A, Table 6). Both amylin and 
CGRP efficacy were enhanced at the I300A mutant but there were no other significant effects for 
either peptide. Within ECL3, the F356A and I371A mutants enhanced efficacy for both peptides, 
while the Y372A mutant attenuated CGRP efficacy and abolished the response to amylin, but no 
other mutants impacted on amylin efficacy. For CGRP, loss of efficacy also occurred at the F359A, 
P360A, D373A and M376A mutants (Figure 11A, Figure 12A, Table 6).  
 
Due to weak coupling of amylin and CGRP to IP1 signalling, effects of mutations on efficacy could 
not be determined.  
 
As noted above for functional affinity data, as coupling of amylin and CGRP to pERK is relatively 
weak, many mutants had responses that could not be operationally quantified. Although some of 
these had selective effects on amylin or CGRP, in these cases the effects on affinity versus efficacy 
could not be separated. 
 
Within ECL2, most mutants either had no quantifiable signalling or did not affect peptide efficacy. 
Lack of signalling occurred for both peptides at the D287A, C289A and W290A mutants. 
Signalling was not quantifiable for L291A and Y299A for CGRP, and attenuated for amylin, while 
  
    
 
amylin signalling was not quantifiable at the T295A mutant, with no effect on CGRP (Figure 11C, 
Figure 12C, Table 6). 
 
Within ECL3, no quantifiable signalling for either peptide was observed for the P360A, D373A and 
I371A mutants. At the Y372A mutant, efficacy was abolished for amylin and attenuated for CGRP. 
Efficacy of both peptides was reduced at the W361A and M376A mutants. It was reduced for 
amylin and abolished for CGRP at the P363A mutant. In general, mutations to the membrane 
proximal segment of TM6/ECL3 had greater impact on CGRP efficacy, with either loss (V357A) or 
attenuation (V358A, F359A, R362A) of efficacy for CGRP with less pronounced effects amylin 
efficacy (Figure 11C, Figure 12C, Table 6). 
 
4. Discussion 
Recent structural biology breakthroughs for the CTR and GLP-1R have provided new 
understanding of class B GPCR peptide binding and receptor activation that includes reorganisation 
of the packing of loop residues, and major, conserved, conformational changes in TM6/ECL3/TM7 
at the extracellular face of the receptor that are linked to outward movement of the intracellular face 
of TM6 to accommodate G protein binding
13-15
. However, these studies also revealed 
peptide/receptor specific differences in presentation of the peptide N-terminus to the core and their 
engagement with the receptor surface, in particular for ECLs 2 and 3. For the GLP-1R, these loops 
play an important role in peptide binding, efficacy and biased agonism
15,16,21
. Intriguingly, the role 
of ECLs 2 and 3 of the CTR was generally distinct when compared to the GLP-1R. This could in 
part be attributed to distinct effector coupling profiles exhibited by the two different receptors with 
the GLP-1R capable of coupling to both G proteins and β-arrestins16, whereas CTR is unable to 
recruit the latter when activated by CT peptides
41
.  
 
  
    
 
4.1 CTR ECL2 plays a key role in conformational propagation linked to Gs/cAMP signalling that 
is distinct from that of GLP-1R ECL2. 
CTR stability, as indexed by cell surface expression, was highly sensitive to mutations in the core of 
ECL2 that formed an interconnected network but were located away from the principal binding site 
for sCT in the active structure. Moreover, mutation of this ECL2 network enhanced efficacy 
selectively for cAMP (all peptides) suggesting that the ECL2 destabilized state is linked to lowered 
barrier for Gs activation, despite decreased affinity of some mutations for peptides (lower pKA). 
Indeed, some mutants demonstrated higher Emax than WT receptor, despite low cell surface 
expression. However, there was limited correlation of the loss of cell surface expression with 
efficacy in other pathways, indicating that this ECL2 conformation is poorly linked to activation of 
other pathways for this receptor. 
 
This segment of ECL2 contains a number of residues that are very highly conserved across the CTR 
and GLP-1R (and indeed all class B GPCRs), including R281/K288 (CTR/GLP-1R amino acids and 
residue number, respectively), C289/C296, W290/W297 and an polar/acidic motif between these 
residues N286,D287,N288 (CTR) and E292,D293,E294 (GLP-1R)
13-15
. Despite this, these residues 
are differentially important in receptor activation between those receptors. With minor exception, 
GLP-1R expression/stability was not markedly affected by mutation for any of the ECLs, including 
ECL2, however, ECL2 was broadly required for both Gs- (cAMP) and Gq- (iCa2+) mediated 
signalling with mutation decreasing peptide efficacy
16,21
. This contrasts with both the enhancement 
of cAMP efficacy for CT peptides, and the very limited importance of ECL2 in CT efficacy for IP1 
signalling (Figures 11, 12 and 13A). Comparison of the Gs complexed structures of the two 
receptors provides some potential insight into why these differences may occur, in particular, there 
are marked differences in positioning of W290/297 and the packing interactions of conserved 
residues around this residue. In the GLP-1R, W297 is completely flipped and buried within the core 
of the loop and this conformation is stabilized by K288, with the acidic/polar residues forming 
  
    
 
additional interactions that stabilize this conformation (Figure 14). In contrast, the aromatic 
functional group of W290 in the CTR remains oriented towards the receptor core with extensive 
interactions observed with sCT and hCT that are stable in MD simulations (Figure 15A, Table 7); 
D287 packs tightly with W290 and C289, while R281 forms alternate interactions to stabilize the 
loop conformation (Figure 14B). The two receptors have very distinct preferred orientations of the 
N-terminal ECD and the peptide ligands enter the receptor core at different angles, with GLP-
1/ExP5 closer to ECL2 such that their entry may require the major reorientation of W297
15
. In this 
vein, it is interesting to note that while alanine mutations of C296 and W297 dramatically 
diminished GLP-1 and exendin-4 binding, they did not alter oxyntomodulin affinity
21
, and it is 
possible that this peptide engages the receptor core in a manner more similar to that observed for 
sCT. For ECL2, CGRP and amylin were generally less affected by mutation and efficacy effects 
were either unmeasurable or only found in a subset of those with altered efficacy for CT peptides.  
 
The CTR shares greatest homology with the calcitonin receptor-like receptor (CLR), including 
strong conservation of residues within ECL2. Unlike CTR, CLR requires RAMP interaction for 
functional cell surface expression and to form CGRP (CGRP1, CLR/RAMP1) or adrenomedullin 
(AM1, CLR/RAMP2; AM2, CLR/RAMP3) receptors. In contrast to the CTR, CLR cell surface 
expression was not greatly impacted by alanine mutation of ECL2 residues
42,43
. However, there 
were similarities in the impact of mutation of conserved residues on cAMP pKA (CTR) or cAMP 
potency (CLR/RAMP receptors). This included reductions in CGRP and adrenomedullin potency, 
for their respective receptors, for R274A (R281A, in CTR), D280A (D287A), C282A (C289A), 
W283A (W297A), and I284A (L291A)
42
 that paralleled the losses in functional affinity seen with 
hCT and pCT, although this could be RAMP-dependent for the adrenomedullin receptors
43
.  
 
Within ECL2, amino acids proximal to the peptide in the sCT/CTR/Gs structure (W290-T295; 
L297,L298) tended to display peptide and/or pathway selective effects. These likely form dynamic 
  
    
 
and differential interactions with key polar residues of the peptides (S
2,sCT/pCT
/G
2,hCT
, N
3
, T
6
, 
Q
14,sCT/hCT
,R
14,pCT
, H
17,sCT
/N
17,hCT/pCT
) to influence peptide binding and signalling (Figure 15A; 
Table 7; Supplementary Movie 1). Of note, T288A, L290A, and L291A of CLR, in a RAMP-
dependent manner, also attenuated adrenomedullin (T288A) or CGRP (T288A,L290A,L291A) 
cAMP potency
42,43
. 
CTR indicated that ECL2 was more conformationally dynamic when the receptor was bound to 
hCT (Supplementary Movie 1), and this may also contribute to the differential effects of mutation 
between CT peptides. 
 
4.2. ECL3 is a gateway for ligand, receptor and pathway specific modulation of class B GPCR 
function 
Across the available active CTR and GLP-1R structures, the largest difference in the receptor core 
was the angle of tilt of TM6, and to a lesser extent TM7, and the interconnecting conformation of 
ECL3, with the CTR exhibiting the greatest outward movement of this domain
13-15
. Nonetheless, 
this was also the region of greatest divergence between the structures of GLP-1/GLP-1R/Gs and the 
G protein-biased analogue complex, ExP5/GLP-1R/Gs, indicating that peptide interactions with 
ECL3 play a critical role in differential modes of receptor activation
15
. Indeed, comparison of the 
effect of mutation in ECL3 across multiple peptides and pathways, and between the CTR and GLP-
1Rs, revealed significant diversity in how ECL3 was engaged and contributed to peptide binding 
and propagation of conformational change linked to efficacy (Figure 13). Interestingly, mutations 
that altered GLP-1R mediated Ca
2+
 (Gq) and pERK primarily clustered within ECL2 and ECL3 
respectively, whereas CTR mutations that altered IP1 (Gq) and pERK displayed similar clustering, 
predominantly within ECL3 that distinct from those required for cAMP. pERK can be activated 
downstream of multiple effector proteins and is often a composite of many divergent signalling 
pathways
16,44
. While pERK1/2 mediated by the GLP-1R is a composite of both G protein and β-
arrestin signalling
16
, the CTR is unable to recruit β-arrestins, suggesting that the pERK response is 
  
    
 
likely to be predominantly G protein mediated
41
. While the CTR can couple to multiple different G 
proteins, similar clustering in our of residues important for IP1 and pERK in our mutational 
analysis suggests that CTR mediated pERK, at least in part, may be downstream of Gq coupling, 
although further experimental data will be required to confirm this. 
 
Despite the diversity in how CTR and GLP-1Rs engage ECL3 to promote signalling, there were 
clear patterns with respect to clustering of residues that were functionally important, particularly 
around the TM6 and TM7 proximal segments of ECL3 that were located with 5Å of the sCT ligand, 
and the network of residues within the loop that stabilized these interactions. For hCT and pCT, the 
sequence of residues at the apex of the TM extension (K366-G369) was important, in a peptide 
specific manner, for IP1 or pERK signalling, indicating that secondary structure in this segment of 
ECL3 contributes to propagation of conformation linked to these pathways for the less well coupled 
peptides. Of particular note were the clear distinctions in the patterns of important residues for pCT 
versus other CT peptides, and CGRP across all peptides suggesting that these peptides have 
different modes of ligand engagement with the receptor relative to the other peptides.  
 
Uniquely among class B GPCR peptide ligands, the CT-family peptides contain an N-terminal 
disulphide bridge between residues 1 and 7 (2 and 7 for CGRP and adrenomedullin), with a 
consequent bulky loop structure that contrasts to the linearly extended GLP-1R peptides observed in 
the active structures. This loop is oriented toward ECL3 and the larger outward movement of this 
domain is required to accommodate the peptide N-terminus. However, the peptides are predicted to 
make relatively weak (non-polar) and transient interactions with ECL3 (Figure 15A; Table 7), and 
this is consistent with the high mobility of TM6/ECL3 in the sCT/CTR/Gs structure that could not 
be resolved at high resolution
13
. Linear analogues of sCT maintain high affinity and potency in 
cAMP signalling, whereas equivalent analogues of hCT have attenuated potency
9,45,46
. sCT has 
higher helical secondary structure propensity in the mid-region of the peptide, compared to hCT
9,47
 
  
    
 
that likely constrains the location of the N-terminus to maintain interactions, whereas the additional 
constraints imposed by the disulphide bridge are required to facilitate interactions for hCT. Greater 
secondary structure of sCT versus hCT is seen in MD simulations of bound peptides (Figure 15C) 
and this contributes to predicted differences in peptide-receptor interactions for these two peptides 
(Figure 15B; Table 7, Supplementary Movie 1). 
 
Intriguingly, comparison of the ExP5, and the GLP-1, receptor complexes, revealed distinct 
positioning of peptides (including minor difference in the relative orientation of the ECD) that 
likely contributes to engagement with ECL3/TM6 and TM7, and this had implications for ligand-
dependent G protein conformations and cAMP signalling efficacy
14,15
. Amongst the cryo-EM 
structures, the GLP-1R complexes exhibited a single major conformation of the ECD relative to the 
receptor core, while the sCT/CTR/Gs complex contained multiple conformations of the ECD that 
were discernible at lower resolution
13
. CT family peptides have a relatively unstructured, and more 
flexible C-terminus than GLP-1 and related peptides
13,48
, and it is likely that there would be greater 
potential for different CT peptides to have altered orientation within the receptor core, relative to 
sCT, as would be predicted from MD simulations (Figure 15C). This would be consistent with the 
differential impact of ECL3 mutation on sCT versus hCT and pCT, and between hCT and pCT (eg. 
for pKA in IP1 and pERK, and efficacy for cAMP and pERK). 
 
Though it is difficult to draw direct comparisons, it is intriguing that select mutation of residues in 
ECL3 differentially affected potency/functional affinity of GLP-1 relative to ExP5
15
, and that this 
was also seen for sCT versus hCT. Like hCT and sCT that have altered Gs-mediated efficacy linked 
to different ligand-induced conformations of Gs
11
, higher efficacy was observed for ExP5 (relative 
to affinity) compared to GLP-1, and this was associated with lower population based assessment of 
max conformational change (hCT, ExP5 versus sCT, Ex4/GLP-1, respectively). This provides the 
  
    
 
first evidence of parallels in the mode of control of efficacy within relatively divergent class B 
subfamily members, albeit that there is still much to understand at a mechanistic level. 
 
Amylin and CGRP are low affinity and potency agonists of CTR but are high potency ligands of 
CTR/RAMP complexes
8
. While this low potency limited analysis for poorly expressed CTR 
mutants, the impact of mutation on amylin was generally consistent with observations for CT 
peptides, especially sCT. In contrast, CGRP had a unique profile, particularly with respect to 
residues within ECL3 and proximal to TM6 (F356A-R362A), indicative of a non-canonical 
spectrum of interaction with this receptor segment. Of note, there were additional CGRP selective 
effects for mutations to CTR residues Y372 and D373 that could make direct peptide interactions, 
and M367 that packs between F356 and F359. Data from the related secretin receptor, has 
implicated TM6/TM7 as the principal membrane interface for RAMP interaction
49
, and this is 
broadly consistent with the data for CLR
13
, albeit that the authors of this latter work reached a 
different conclusion. While CTR and CLR interactions are more complex, with additional 
interaction between RAMP and receptor ECDs that contribute to altered peptide affinities
48-50
, a 
TM6 interface would be consistent with the key role of ECL3 in biased signalling, and with the 
predicted impact of RAMP interactions on the conformation of ECL3 for adrenomedullin 
receptors
43
. RAMPs alter signalling profiles for multiple class B GPCRs, including glucagon, 
VPAC1 and CT receptors
50-55
, even where altered binding phenotypes are not observed. The nature 
of the RAMP-induced enhancement of CGRP binding and potency at the CTR is particularly 
complex, with RAMP chimera and truncation studies indicative of a direct role of the short RAMP 
C-terminus in G protein engagement that is critical for CGRP potency
56-57
, and this may also 
allosterically regulate CGRP engagement with ECL3. ECL3 was also important for cAMP 
signalling of CGRP or adrenomedullin at CLR/RAMP complexed receptors. Similar to observations 
for CT peptides at the CTR, both common and peptide specific effects were observed
58-60
, 
confirming the dynamic role that ECL3 plays in this receptor subfamily. However, as the signalling 
  
    
 
data were not separated into the derivative effects on affinity and efficacy, it is difficult to make 
specific comparisons. Understanding the impact of RAMPs on CTR binding and activation by 
peptides will require additional structures and mutants of RAMP-complexed receptors. 
 
Integration of alanine scanning analysis of the critically important ECLs 2 and 3, on peptide 
function, with new insights available from novel peptide-bound, active state, G protein complexed 
class B receptors, has revealed marked diversity in mechanisms of peptide engagement and receptor 
activation between the CTR and GLP-1R. A significant contributor appears to be the orientation of 
peptides within the receptor core, and this will be influenced by relative orientation of the ECD that 
engages the peptide C-terminus. While both domains play important functional roles, ECL3 appears 
to be a hotspot for distinct ligand and pathway specific effects, and this has implications for the 
future design of biased agonists of class B GPCRs.  
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Figure 1. Alanine mutation of ECL2 and ECL3 of the hCTR selectively alters expression of 
the receptor. (A) Alignment of CT and related peptide sequences was performed using Biology 
WorkBench (workbench.sdsc.edu). Identical residues are highlighted in green, conservative 
substitutions are coloured blue, and semi- conservative substitutions are in orange. Black text 
indicates the non-conserved. (B) Snake diagram of the hCTR: highlighted in blue are the residues 
that constitute the signal peptide of the receptor, in orange the c-Myc tag, and in green the residues 
that have been mutated to alanine. (C) Active state model of the hCTR (pale blue ribbon), with 
position of mutated residues displayed as grey surface map. sCT is shown as dark red, with side 
chains in proximity to the ECLs displayed in x-stick, and residues 1-7 that are critical for receptor 
activation displayed in transparent cpk. (D) Expression of mutant receptors determined by FACS 
analysis of antibody binding to the c-Myc epitope. (E) Top view of the ECLs with mutants that 
significantly altered receptor expression displayed in colour according to the magnitude of effect; 
grey indicates no significant effect and black mutants where expression could not be measured. The 
receptor ECD and C-terminal peptide residues are omitted for clarity (F). There was a strong 
correlation between cell surface receptor expression by FACS and homologous competition 
radioligand binding. *P<0.05, one-way ANOVA with Dunnett’s post-test. Data are mean + S.E.M. 
(D) or ± S.E.M. (F) of 3 to 6 (WT 10 to 12) independent experiments. 
 
Figure 2. Alanine mutation of ECL2 and ECL3 of the hCTR alters CT peptide binding pKi 
and functional affinity (pKA) in a peptide- and pathway- specific manner. The effect of 
mutation on peptide affinity in competition for the antagonist radioligand 
125
I-sCT(8-32) is 
displayed as pKi in the upper panels, with functional affinities derived from operation fitting of 
concentration-response curves in cAMP accumulation, pERK and IP1 accumulation displayed as 
pKA in the mid and lower panels, respectively. Illustrated is a top view of the active, sCT-bound, 
hCTR model with ECL2 and ECL3 shown in surface representation. Mutations that significantly 
alter peptide affinity are coloured according the magnitude of effect (from Tables 1 and 5), with 
  
    
 
mutated amino acids without significant alteration to affinity coloured grey. sCT is shown as dark 
red, with side chains in proximity to the ECLs displayed in x-stick, and residues 1-7 that are critical 
for receptor activation displayed in transparent cpk. 
 
Figure 3. Competition of 
125
I-sCT(8-32) binding by CT peptides for wild-type (WT) and each of 
the hCTR mutants stably expressed in CV1- FlpIn cells. Whole cell radioligand binding was 
performed for each receptor mutant in presence of 
125
I-sCT(8-32) and competing peptide ranging in 
concentration between 1 μM and 1 pM  Non-specific binding was determined in the presence of 1 
μM of s T(8-32) and was used to calculate % of specific binding. Data were fit with a three-
parameter logistic equation. All values are mean + S.E.M. of 3 to 12 (WT 16 to 18) independent 
experiments, conducted in duplicate.  
 
Figure 4. cAMP accumulation profiles elicited by sCT, hCT, pCT, rat amylin (rAmy) or hCGRP in 
CV1-FlpIn cells stably expressing wild-type (WT) or single alanine mutations of ECL2 or ECL3. 
cAMP formation in the presence of agonist peptides was normalized to responses of the internal 
control (0.1 mM forskolin) and fit to a three-parameter logistic equation. Data was subsequently 
normalised to WT receptor response. All values are mean + S.E.M. of 4 to 11 (WT 25 to 36) 
independent experiments conducted in duplicate. 
 
Figure 5. IP1 accumulation profiles elicited by sCT, hCT, or pCT in CV1-FlpIn cells stably 
expressing wild-type (WT) or single alanine mutations of ECL2 or ECL3. IP1 accumulation in the 
presence of agonist peptides was normalized to responses of the internal control (0.1 mM ATP) and 
fit to a three-parameter logistic equation. Data was subsequently normalised to WT receptor 
response. All values are mean + S.E.M. of 4 to 7 (WT 37 to 47) independent experiments conducted 
in duplicate. 
 
  
    
 
Figure 6. Peak ERK1/2 phosphorylation (pERK) profiles elicited by sCT, hCT, pCT, rat amylin 
(rAmy) or hCGRP in CV1-FlpIn cells stably expressing wild-type (WT) or single alanine mutations 
of ECL2 or ECL3. pERK in the presence of agonist peptides was normalized to the WT receptor 
response and fit to a three-parameter logistic equation. All values are mean + S.E.M. of 4 to 6 (WT 
30 to 35) independent experiments conducted in duplicate. 
 
Figure 7. Correlation between changes in global peptide affinity (pKi) derived from heterologous 
competition binding assays, and functional pKA for cAMP (upper panels), IP1 (middle panels) or 
pERK (bottom panels) signalling, for hCT (left hand panels), sCT (middle panels) or pCT (right 
hand panels). For all peptides, the highest correlation was seen between pKi and pKA derived from 
operational analysis of cAMP response data. Significant but weaker correlations were also observed 
between pKi and functional affinities for IP1 and pERK signalling for hCT, and for pERK 
signalling alone for pCT. No correlation was observed for sCT pKA values from IP1 or pERK 
assays or pCT IP1 assays. 
 
Figure 8. Alanine mutation of ECL2 and ECL3 of the hCTR selectively alters peptide 
functional affinity in a pathway-dependent manner. For each receptor mutant and ligand, 
concentration-response data for (A) cAMP accumulation, (B) IP1 accumulation, or (C) pERK 
assays were fit with the Black and Leff operational model to derive a functional affinity (pKA) for 
each pathway, and these values were subtracted from the WT pKA  alues to yield ΔpKA. All values 
are mean + S.E.M. of 4 to 11 (WT 25 to 47) independent experiments conducted in duplicate. 
Significance of changes were determined by comparison of the WT to the other receptor mutants in 
a one-way analysis of  ariance and Dunnett’s post-test of determined pKA values (Table 5) with 
significant changes (P<0.05) denoted by *, and coloured according to the magnitude of effect. N.D., 
functional affinity not determined. 
 
  
    
 
Figure 9. Mutants that differentially alter peptide-dependent functional affinity cluster into 
subdomains in ECL2 and ECL3. (A-C) Mutants that alter functional affinity are displayed in x-
stick representation, coloured according to effect on the different signalling pathways. (A) Effect of 
mutation on sCT, (B) hCT, or (C) pCT pKA. Mutants that did not significantly affect functional 
affinity in any pathway are coloured grey. The full receptor TM domain is displayed as grey ribbon, 
and sCT in dark red ribbon, with the receptor ECD, and peptide C-terminal residues omitted for 
clarity. (D) ECL2 and ECL3 amino acids within 5Å of sCT in the model are displayed in red 
transparent cpk representation.  
 
Figure 10. Alanine mutation of ECL2 and ECL3 of the hCTR alters amylin and CGRP 
functional affinity (pKA) in a peptide- and pathway- specific manner. Functional affinities 
derived from operation fitting of concentration-response curves in cAMP accumulation (upper 
panel) and pERK (lower panel) are displayed as pKA. Illustrated is a top view of the active, sCT-
bound, hCTR model with ECL2 and ECL3 shown in surface representation. Mutations that 
significantly alter peptide affinity are coloured according the magnitude of effect (from Table 5), 
with mutated amino acids without significant alteration to affinity coloured grey. sCT is shown as 
dark red, with side chains in proximity to the ECLs displayed in x-stick, and residues 1-7 that are 
critical for receptor activation displayed in transparent cpk. 
 
Figure 11. Alanine mutation of ECL2 and ECL3 of the hCTR selectively alters peptide 
efficacy. Concentration-response data for each peptide in (A) cAMP accumulation, (B) IP1 
accumulation, or (C) pERK assays were fit to the operational model of agonism to calculate the 
affinity-independent coupling efficacy log(τ) of each receptor (mutant or WT) for each signalling 
pathway  The log(τ)  alues of each receptor were then corrected for expression to obtain log(τc)  
Graphs show the differences relative to WT. All values are mean +/- S.E.M. of 4 to 11 (WT 25 to 
47) independent experiments conducted in duplicate. Significance of changes were determined by 
  
    
 
comparison of the WT to the other receptor mutants in a one-way analysis of variance and 
Dunnett’s post-test of determined log(τc)  alues (Table 2) with significant changes (P<0 05) 
denoted by *, and coloured according to the magnitude of effect. N.D., efficacy not determined. 
 
Figure 12. Alanine mutation of ECL2 and ECL3 of the hCTR differentially modulates CT and 
related peptide efficacy in a pathway-dependent manner. Illustrated are top views of the active, 
sCT-bound, hCTR model with ECL2 and ECL3 shown in surface representation. Mutations that 
significantly alter peptide efficacy are coloured according the magnitude of effect (from Table 6 and 
Figure 11), with mutated amino acids without significant alteration to efficacy coloured grey. 
Salmon CT is shown as dark red, with side chains in proximity to the ECLs displayed in x-stick, 
and residues 1-7 that are critical for receptor activation display in transparent cpk. (A) Changes to 
cAMP efficacy. (B) Changes to IP1 efficacy. (C) Changes to pERK efficacy. 
 
Figure 13.  Comparison of the effect of alanine-scanning mutagenesis of ECL2 and ECL3 on 
cAMP (A) and pERK (B) efficacy of sCT at the CTR or exendin-4 at the GLP-1R. Top views 
of active state structures of sCT/hCTR/Gs or Ex-P5/hGLP-1R/Gs, with the receptor ECD and 
peptide C-terminus omitted for clarity. Mutations that significantly alter peptide efficacy are 
coloured according the magnitude of effect, with mutated amino acids without significant alteration 
to efficacy coloured grey. Efficacy data for exendin-4 (Ex4) are from Wootten et al., 2016, and are 
mapped onto the structure of exendin-P5/hGLP-1R/Gs (PDB: 6B3J). sCT is shown as dark red, 
with side chains in proximity to the ECLs displayed in x-stick, and residues 1-7 that are critical for 
receptor activation displayed in transparent cpk. Exendin-P5 is shown as dark blue, with side chains 
in proximity to the ECLs displayed in x-stick, and residues 1-8 that are important for receptor 
activation displayed in transparent cpk. 
 
  
    
 
Figure 14. CTR and GLP-1R have distinct conformations of ECL2 that are differentially 
stabilised by conserved residues in the core of the loop. (A) GLP-1R displaying loop residues in 
red x-stick and the highly conserved C296, W297 and K288 residues displayed in transparent cpk 
representation. Shown in orange are GLP-1R residues in the conserved polar network E292, D293, 
and E294. (B) CTR displaying loop residues in green x-stick and the highly conserved C289, W290 
and R281 residues displayed in transparent cpk representation. Shown in light green are the CTR 
residues in the equivalent conserved polar network N286, D287, and N288. Ribbon representations 
of the proximal amino acids of exendin-P5 (blue) or sCT (dark red) are also displayed. 
 
Figure 15. Molecular dynamic simulations of sCT and hCT peptide-receptor interaction. 
The CT residues least engaged by the receptor (0% contact) are coloured blue, while residues most 
engaged by the receptor (100% contact) are coloured red. (A) hCT (magenta), (B) sCT (magenta). 
(C) 
simulation of sCT bound to CTR, as determined using VMD. 
 
Supplementary Movie 1. Interactions between hCT (left hand panel) or sCT (right hand 
 Interactions between hCT and the CTR are less 
stable than those of sCT and the receptor. As a consequence, ECL2 in the hCT-bound CTR 
undergoes more dynamic conformational sampling. 
  
  
    
 
Table 1. Effect of single alanine mutation in hCTR ECL2 or ECL3 on binding affinity (pKi) of 
CT peptides, and receptor cell surface expression.  
 
hCT sCT pCT sCT(8-32) FACS Bmax 
pKi pKi pKi pKi (% of WT) (sites/cell) 
WT 6.72±0.06 (16) 9.87±0.03 (16) 8.27±0.07 (17) 9.70±0.05 (18) 100 (12) 22,900±2,500 (10) 
I279A 6.16±0.08 (3) 9.93±0.18 (4) 7.83±0.24 (4) 9.72±0.08 (8) 113±7 (4) 40,500±11,300 (5) 
T280A 6.71±0.05 (4) 10.2±0.03 (4) 8.20±0.15 (4) 9.61±0.08 (8) 142±11 (4) 62,600±8,700* (4) 
R281A 5.92±0.28* (5) 9.10±0.15* (6) 7.18±0.23* (5) 9.07±0.21* (10) 32±4* (6) 24,900±10,200 (3) 
V283A 6.63±0.11 (4) 9.78±0.14 (4) 7.82±0.08 (4) 9.67±0.03 (8) 93±11 (4) 47,600±13,600 (4) 
Y284A 6.61±0.11 (5) 9.83±0.07 (3) 7.84±0.10 (4) 9.85±0.10 (8) 72±9* (4) 37,800±12,800 (4) 
F285A 6.60±0.11 (4) 10.0±0.12 (4) 7.92±0.11 (4) 9.99±0.05 (8) 96±15 (4) 33,200±11,000 (4) 
N286A N.D. N.D. N.D. N.D. 26±4* (4) N.D. 
D287A N.D. N.D. N.D. N.D. 5±1* (4) N.D. 
N288A 6.35±0.12 (4) 9.74±0.13 (4) 8.03±0.12 (5) 9.63±0.04 (8) 132±16 (4) 51,600±2,600* (4) 
C289A N.D. N.D. N.D. N.D. 13±3* (3) N.D. 
W290A N.D. N.D. N.D. N.D. 19±6* (4) N.D. 
L291A 5.41±0.10* (3) 9.75±0.21 (5) 7.17±0.12* (6) 8.76±0.19* (9) 109±15 (4) 55,700±27,400 (3) 
S292A 6.60±0.05 (4) 10.4±0.20* (4) 8.54±0.22 (4) 10.2±0.13 (8) 78±14 (4) 11,600±3,600 (4) 
V293A 6.22±0.08 (4) 9.59±0.05 (4) 7.85±0.10 (4) 9.75±0.08 (8) 101±12 (4) 39,500±13,000 (4) 
E294A 6.73±0.06 (5) 9.77±0.08 (4) 7.93±0.10 (4) 9.58±0.07 (8) 103±12 (4) 48,700±10,100 (4) 
T295A 5.90±0.050* (4) 10.2±0.16 (4) 7.49±0.08* (4) 10.3±0.09* (8) 27±6* (4) 6,600±2,300* (4) 
H296A 6.95±0.13 (4) 9.84±0.09 (4) 8.07±0.03 (4) 9.57±0.07 (8) 82±11 (4) 65,500±5,100* (4) 
L297A 6.09±0.05* (4) 10.1±0.15 (4) 7.81±0.19 (4) 10.2±0.07 (8) 29±3* (4) 9,200±2,000* (4) 
L298A 6.13±0.08* (4) 9.76±0.09 (4) 7.69±0.10 (4) 9.83±0.12 (8) 59±14 (4) 19,600±4,000 (4) 
Y299A 6.28±0.02 (4) 9.41±0.20 (4) 7.33±0.20* (4) 9.97±0.18 (8) 43±16* (4) 11,100±1,900* (4) 
I300A N.D. N.D. N.D. N.D. 11±1* (4) N.D. 
F356A 6.58±0.11 (5) 9.79±0.34 (5) 7.92±0.17 (4) 9.85±0.25 (12) 28±4* (6) 5,900±2,200* (5) 
V357A 6.13±0.13* (5) 9.83±0.18 (4) 7.89±0.27 (4) 9.68±0.10 (8) 104±14 (4) 28,400±7,700 (4) 
V358A 5.89±0.15* (5) 9.62±0.09 (4) 7.84±0.13 (4) 9.81±0.06 (8) 103±18 (4) 34,100±10,500 (4) 
F359A 5.49±0.12* (5) 9.50±0.15 (4) 7.13±0.19* (3) 9.66±0.10 (10) 158±28 (4) 40,400±9,200 (4) 
P360A 5.65±0.06* (5) 9.01±0.13* (4) 7.30±0.28* (4) 9.22±0.10* (10) 320±35* (5) 89,400±15,800* (5) 
W361A 5.99±0.08* (5) 9.48±0.08 (4) 7.47±0.24* (4) 9.55±0.11 (10) 139±22 (4) 46,200±18,200 (5) 
R362A 5.96±0.06* (4) 9.53±0.13 (4) 7.33±0.22* (4) 9.66±0.14 (8) 71±9* (4) 27,300±1,000 (4) 
P363A 5.48±0.26* (4) 9.44±0.14 (4) 7.26±0.13* (4) 9.45±0.23 (8) 81±7 (4) 19,400±5,800 (4) 
S364A 6.61±0.07 (4) 9.73±0.06 (4) 8.27±0.34 (4) 9.72±0.08 (10) 88±16 (4) 32,600±11,200 (5) 
N365A 6.68±0.16 (4) 9.96±0.06 (4) 8.68±0.24 (4) 9.63±0.10 (10) 116±13 (4) 29,400±11,900 (5) 
K366A 6.47±0.17 (4) 9.69±0.05 (4) 7.96±0.23 (4) 9.71±0.12 (10) 119±14 (4) 43,000±16,000 (5) 
M367A 6.24±0.11 (4) 9.67±0.09 (4) 7.67±0.25 (4) 9.53±0.14 (8) 94±112 (4) 25,600±7,900 (4) 
L368A 6.50±0.13 (4) 9.81±0.04 (4) 8.07±0.19 (4) 9.68±0.11 (8) 89±9 (4) 28,200±13,100 (4) 
G369A 6.41±0.10 (4) 9.89±0.02 (4) 8.10±0.19 (4) 9.64±0.14 (10) 133±20 (4) 40,600±18,800 (5) 
K370A N.D. N.D. N.D. N.D. N.D. N.D. 
I371A N.D. N.D. N.D. N.D. 3±1* (3) N.D. 
Y372A 6.09±0.09* (4) 9.40±0.06 (4) 7.55±0.27* (4) 9.85±0.19 (8) 98±13 (4) 21,700±8,600 (4) 
D373A 5.76±0.22* (6) 9.36±0.09* (4) 7.76±0.28 (4) 9.28±0.15 (8) 98±14 (4) 43,500±22,700 (5) 
Y374A 6.64±0.17 (4) 9.79±0.13 (4) 8.23±0.09 (4) 9.83±0.13 (8) 65±5* (4) 26,300±7,500 (4) 
V375A 6.48±0.19 (5) 9.83±0.08 (4) 8.29±0.25 (4) 9.72±0.09 (8) 115±13 (3) 22,500±8,000 (4) 
M376A 6.06±0.21* (6) 9.80±0.15 (6) 8.11±0.24 (4) 9.88±0.10 (8) 113±7 (4) 23,600±3,200 (4) 
 
pKi values were derived for each ligand and mutant receptor from analysis of either homologous (sCT(8-32)) or heterologous (sCT, 
hCT, pCT) competition of [125]I-sCT(8-32) binding. The number of receptors per cell (Bmax) was estimated from homologous 
competition studies. All values are mean ± S.E.M. (independent “n” values are indicated within parentheses). Cell surface receptor 
expression was determined by FACS using an anti-c-myc antibody, and expression normalized to WT expression and expressed as 
%WT. Significance of changes in receptor expression, or pKi of each ligand, was determined by comparison of mutant receptors to 
WT values by a one-way analysis of variance and Dunnett’s post-test for affinity data, and two-tailed t-test for expression data 
(p<0.05 represented by *). (N.D.) affinity not determined as no radioligand binding was detected. 
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Table 2: Effect of single alanine mutation in hCTR ECL2 or ECL3 on cAMP signalling in response to CT-family 
peptides.  
 
hCT sCT pCT rAmy hαCGRP  
pEC50 
Emax (% 
WT) 
N pEC50 
Emax (% 
WT) 
N pEC50 
Emax (% 
WT) 
N pEC50 
Emax 
(% 
WT) 
N pEC50 
Emax 
(% 
WT) 
N 
WT 
9.93±0.0
6 
100±2 
(36
) 
10.7±0.
05 
100±1 
(36
) 
10.4±0.10 100±2 
(31
) 
8.05±0.
11 
100±4 
(31
) 
7.96±0.
21 
100±
7 
(25
) 
I279A 
10.3±0.1
8 
91±4 (4) 
11.1±0.
25 
90±6 (5) 10.4±0.15 97±4 (6) 
8.53±0.
35 
81±9 (5) 
8.47±0.
41 
139±
18 
(5) 
T280
A 
10.3±0.2
8 
97±6 (4) 
11.3±0.
56 
107±14 (4) 10.4±0.17 113±5 (5) 
8.47±0.
38 
69±8 (4) 
8.48±0.
49 
107±
21 
(5) 
R281
A 
7.22±0.2
6* 
117±15 (8) 
10.4±0.
17 
119±5 
(11
) 
9.19±0.28
* 
147±16* (6) 
7.36±0.
5 
63±14 (5) 
7.41±0.
43 
114±
25 
(5) 
V283
A 
10.4±0.3
4 
90±7 (4) 
11.1±0.
38 
116±12 (5) 10.5±0.32 107±9 (5) 
8.17±0.
36 
77±10 (5) 
7.89±0.
39 
130±
19 
(5) 
Y284
A 
10.2±0.3
5 
103±10 (5) 
11.0±0.
35 
111±11 (5) 10.2±0.29 104±9 (6) 
7.99±0.
25 
101±1
0 
(5) 
7.72±0.
39 
139±
22 
(5) 
F285
A 
9.97±0.4
2 
105±11 (5) 
11.1±0.
29 
105±8 (5) 10.3±0.45 81±10 (6) 
8.17±0.
28 
92±9 (5) 
7.80±0.
39 
122±
18 
(5) 
N286
A 
9.37±0.1
7 
126±6 (5) 
10.8±0.
22 
103±6 (5) 9.70±0.22 84±6 (5) 
7.35±0.
35 
97±15 (5) 
7.85±0.
75 
46±1
6 
(5) 
D287
A 
7.53±0.3
0* 
140±18* (6) 
10.3±0.
22 
119±7 
(10
) 
8.72±0.34
* 
74±9 (6) N.D. N.D.  N.D. N.D.  
N288
A 
9.99±0.3
2 
117.0±1
0 
(5) 
11.2±0.
28 
69±5* (6) 10.2±0.31 105±10 (5) 
8.52±0.
44 
64±8 (5) 
7.99±0.
34 
118±
17 
(5) 
C289
A 
7.92±0.2
1* 
148±7* (8) 
10.3±0.
17 
140±7* 
(10
) 
8.99±0.16
* 
115±7 (8) 
7.17±0.
48 
89±23 (5) N.D. N.D.  
W29
0A 
7.13±0.2
4* 
164±20* 
(10
) 
10.5±0.
16 
154±7* 
(11
) 
8.48±0.28
* 
113±12 (5) 
7.09±0.
55 
72±26 (5) N.D. N.D.  
L291
A 
8.36±0.1
1* 
131±5* 
(10
) 
10.9±0.
14 
108±4 
(10
) 
9.50±0.14
* 
105±5 (6) 
7.74±0.
31 
101±1
3 
(5) 
7.29±0.
64 
101±
36 
(5) 
S292
A 
9.95±0.3
5 
135±13 (6) 
11.1±0.
38 
119±12 (6) 10.5±0.26 131±9* (6) 
8.39±0.
32 
95±10 (6) 
7.65±0.
30 
106±
14 
(5) 
V293
A 
10.1±0.2
4 
123±8 (5) 
10.9±0.
35 
112±11 (5) 10.3±0.18 107±5 (6) 
8.13±0.
29 
91±10 (6) 
8.06±0.
29 
153±
17 
(5) 
E294
A 
10.3±0.2
0 
105±5 (5) 
11.1±0.
31 
98±9 (5) 10.4±0.22 105±6 (5) 
7.92±0.
26 
90±9 (5) 
7.31±0.
49 
137±
31 
(5) 
T295
A 
9.44±0.3
1 
127±11 (5) 
10.5±0.
31 
138±13* (5) 9.55±0.21 123±8 (5) 
7.36±0.
48 
74±19 (5) 
6.97±0.
42 
79±2
0 
(5) 
H296
A 
10.5±0.1
9 
87±4 
(10
) 
11.0±0.
18 
86±5 
(10
) 
10.5±0.29 96±8 (5) 
8.29±0.
48 
107±1
8 
(5) 
7.85±0.
41 
106±
18 
(6) 
L297
A 
9.75±0.2
5 
91±6 (4) 
10.8±0.
4 
103±12 (4) 10.0±0.20 127±8 (6) 
7.87±0.
30 
85±10 (5) 
7.44±0.
34 
88±1
4 
(5) 
L298
A 
9.44±0.2
0 
103±6 (5) 
10.7±0.
3 
112±9 (5) 10.2±0.20 118±7 (5) 
8.21±0.
30 
117±1
3 
(5) 
7.47±0.
36 
109±
17 
(5) 
Y299
A 
9.33±0.2
2 
133±9 (5) 
10.9±0.
25 
110±7 (5) 9.87±0.23 117±9 (6) 
7.71±0.
25 
102±1 (4) 
7.48±0.
55 
62±1
6 
(5) 
I300A 
9.83±0.1
8 
116±6 (5) 
10.7±0.
36 
113±11 (5) 10.3±0.30 117±11 (5) 
7.61±0.
22 
109±1
0 
(5) 
7.71±0.
45 
73±1
4 
(5) 
F356
A 
8.71±0.1
8* 
131±8* (5) 
10.9±0.
05 
100±1 (6) 10.5±0.07 100±2 (4) 
7.62±0.
30 
126±1
5 
(4) 
7.18±0.
11 
128±
10 
(5) 
V357
A 
9.15±0.1
4* 
137±6* (6) 
10.3±0.
32 
133±12* (6) 9.82±0.35 154±17* (4) 
7.69±0.
27 
88±10 (5) 
7.53±0.
32 
82±1
0 
(5) 
V358
A 
9.72±0.1
6 
98±4 (4) 
10.8±0.
24 
139±9* (4) 10.5±0.38 140±15* (4) 
7.86±0.
36 
94±13 (4) 
7.68±0.
31 
74±9 (5) 
F359
A 
8.95±0.2
4* 
130±9* (5) 
11.0±0.
18 
84±4.0 (5) 9.79±0.25 113±8 (4) 
7.63±0.
25 
95±9 (5) 
7.73±0.
41 
53±8
* 
(5) 
P360
A 
8.80±0.1
7* 
152±8* (5) 
11.0±0.
18 
100±5 (5) 9.88±0.27 146±13 (4) 
7.63±0.
30 
115±1
3 
(5) 
7.76±0.
28 
48±5
* 
(5) 
W36
1A 
9.32±0.2
5 
132±9* (5) 
10.6±0.
19 
126±7* (5) 9.83±0.20 133±9* (4) 
7.79±0.
31 
102±1
3 
(5) 
7.01±0.
30 
102±
16 
(5) 
R362
A 
8.68±0.2
4* 
125±9* (4) 
10.8±0.
14 
95±4 (4) 9.74±0.21 138±9* (4) 
7.61±0.
32 
88±12 (4) 
7.75±0.
48 
51±9
* 
(5) 
P363
A 
8.74±0.1
3* 
111±5 (5) 
10.3±0.
28 
111±9 (5) 
9.41±0.34
* 
148±15* (4) 
7.82±0.
55 
94±20 (6) 
7.41±0.
47 
38±7
* 
(5) 
S364
A 
9.94±0.3
6 
97±9 (5) 
10.8±0.
26 
102±7 (5) 
9.22±0.29
* 
166±16* (4) 
8.35±0.
38 
56±7* (4) 
7.78±0.
31 
83±1
0 
(4) 
N365
A 
9.91±0.1
6 
96±4 (5) 
10.8±0.
19 
94±5 (5) 10.5±0.21 95±5 (4) 
8.18±0.
32 
72±8 (4) 
7.81±0.
31 
111±
13 
(5) 
K366
A 
10.1±0.1
7 
74±3* (5) 
10.9±0.
23 
81±5* (5) 10.7±0.39 80±8 (4) 
8.02±0.
26 
71±7 (4) 
8.27±0.
54 
73±1
3 
(5) 
M36
7A 
10.0±0.1
9 
82±4 (5) 
10.9±0.
16 
79±3* (5) 10.8±0.34 73±13 (4) 
8.30±0.
26 
93±8 (4) 
7.67±0.
31 
114±
14 
(5) 
L368
A 
10.1±0.2
3 
70±4* (5) 
11.1±0.
33 
75±7* (5) 10.5±0.26 96±6 (4) 
7.93±0.
34 
95±12 (5) 
7.94±0.
4 
78±1
2 
(5) 
G369
A 
9.92±0.2
7 
129±9* (5) 
10.8±0.
27 
106±8 (5) 9.69±0.28 89±7 (4) 
7.83±0.
20 
78±6 (4) 
7.61±0.
38 
131±
20 
(5) 
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K370
A 
N.D. N.D.  N.D. N.D.  N.D. N.D.  N.D. N.D.  N.D. N.D.  
I371A 
9.99±0.4
7 
24±2.7* (5) 
11.2±0.
30 
28±2* (5) 10.1±0.21 35±5* (4) 
8.73±0.
60 
47±7* (5) 
6.88±0.
54 
58±1
5* 
(5) 
Y372
A 
8.03±0.2
0* 
149±12.
* 
(4) 
10.0±0.
27 
113±10 (4) 
8.94±0.24
* 
137±13* (4) 
6.73±0.
26 
170±2
6* 
(5) 
6.91±0.
45 
36±8
* 
(5) 
D373
A 
9.20±0.1
9 
142±8* (4) 
10.8±0.
25 
116±8 (4) 
9.41±0.16
* 
158±9* (4) 
7.98±0.
70 
64±16 (5) 
7.95±0.
41 
34±5
* 
(5) 
Y374
A 
9.78±0.2
3 
83.2±5 (5) 
10.9±0.
18 
96±5 (5) 10.7±0.39 90±9 (4) 
8.10±0.
24 
92±9 (4) 
7.60±0.
36 
82±1
2 
(5) 
V375
A 
9.79±0.2
2 
122±7* (5) 
10.6±0.
17 
106±5 (5) 10.5±0.21 151±8* (4) 
8.10±0.
27 
92±9 (5) 
7.69±0.
38 
114±
17 
(5) 
M37
6A 
8.44±0.3
7* 
84.3±10 (5) 
10.6±0.
20 
102±6 (5) 9.63±0.40 87±11* (4) 
7.33±0.
34 
85±13 (5) 
6.85±0.
26 
47±7
* 
(5) 
 
For each receptor and ligand, data were fit to a three-parameter logistic equation to derive pEC50 (negative 
logarithm of the concentration of ligand that produces half the maximal response) and Emax (maximal 
response, as % of WT). All values are mean ± S.E.M. (independent “n” values are indicated within 
parentheses). For each ligand, significance of changes in pEC50 and Emax were determined by comparison of 
mutants to the WT receptor in a one-way analysis of variance followed by Dunnett’s post-test (p<0.05 
represented by *). (N.D.) pEC50 or Emax not determined.  
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Table 3:   Effect of single alanine mutation in hCTR ECL2 or ECL3 on IP1 signalling in response to CT peptides.  
 
hCT sCT pCT 
pEC50 Emax (% WT) N pEC50 Emax (% WT) N pEC50 Emax (% WT) N 
WT 8.80±0.07 100±3 (47) 9.24±0.5 100±3 (44) 8.86±0.13 100±3 (37) 
I279A 8.08±0.25 79±7 (7) 8.72±0.23 97±7 (7) 8.18±0.22 116±10 (5) 
T280A 7.68±0.20* 79±6 (6) 8.89±0.12 119±5 (7) 8.61±0.21 100±6 (7) 
R281A 7.96±0.37* 30±4 (7) 9.03±0.23 91±6 (6) 8.65±0.23 52±4* (6) 
V283A 7.60±0.21 67±6* (5) 8.87±0.15 115±6 (7) 8.21±0.14 100±5 (7) 
Y284A 7.71±0.37 81±12 (7) 8.94±0.20 118±7 (6) 8.94±0.20 94±6 (7) 
F285A 7.99±0.27 58±6* (6) 8.59±0.17 114±6 (5) 8.30±0.32 112±13 (6) 
N286A 8.82±0.28 40±3* (6) 8.93±0.26 59±5* (5) 9.25±0.27 76±6 (7) 
D287A N.D N.D  N.D. N.D.  8.43±0.38 56±7* (6)
N288A 7.78±0.22* 91±8 (7) 8.80±0.15 119±6 (6) 8.72±0.25 93±7 (7) 
C289A N.D. N.D.  8.52±0.28 42±4* (6) N.D N.D (7) 
W290A N.D. N.D.  N.D N.D  N.D N.D  
L291A 6.28±0.53* 71±16* (7) 8.73±0.14 85±4 (7) 8.79±0.31 67±6* (7) 
S292A 7.51±0.20* 70±6 (6) 8.86±0.21 91±6 (7) 8.37±0.23 92±7 (7) 
V293A 8.12±0.13 87±4 (6) 9.21±0.22 109±7 (7) 8.49±0.27 112±10 (5) 
E294A 8.21±0.27 57±6* (6) 8.62±0.18 84±5 (6) 8.89±0.22 119±8 (6) 
T295A 8.31±0.27 43±4* (6) 8.11±0.33* 53±7* (6) 8.34±0.37 56±7* (6) 
H296A 7.98±0.19* 73±6* (7) 9.34±0.19 101±5 (7) 8.35±0.21 101±7 (6) 
L297A 7.68±0.25* 52±5* (7) 9.12±0.32 69±7* (6) 8.70±0.25 68±5* (7) 
L298A 7.69±1.10 58±6* (7) 8.88±0.22 66±5* (7) 8.39±0.25 91±10 (5) 
Y299A 7.94±0.37 34±5* (6) 8.19±0.27* 54±5* (6) 9.38±0.25 52±3* (7) 
I300A 8.12±0.37 44±4* (6) N.D N.D  N.D. N.D.  
F356A 7.95±0.20* 69±6* (6) 9.23±0.29 36±3* (6) N.D N.D  
V357A 7.61±0.23* 50±4* (5) 8.90±0.20 39±3* (5) 7.81±0.20* 48±4* (5) 
V358A 7.64±0.18* 126±9* (6) 8.76±0.15 123±6* (6) 8.48±0.26 73±6* (5) 
F359A 7.29±0.20* 101±9 (5) 8.72±0.14 125±6* (5) 7.88±0.18* 77±6 (5) 
P360A 7.06±0.16* 95±8 (5) 8.55±0.11* 144±5* (6) 7.07±0.23* 107±12 (5) 
W361A 7.77±0.26 89±9 (6) 9.01±0.18 108±6 (5) 8.08±0.19* 80±6 (6) 
R362A 7.47±0.34* 77±11 (6) 8.74±0.22 64±5* (5) 7.71±0.50* 47±9* (6) 
P363A N.D. N.D.  9.27±0.35 86±9 (5) 8.21±0.38 73±10* (6) 
S364A 7.77±0.21* 93±8 (5) 8.79±0.21 87±6 (5) 8.16±0.29 93±6 (5) 
N365A 8.36±0.21 81±6 (5) 8.96±0.18 66±4* (4) 8.65±0.29 68±6* (5) 
K366A 8.58±0.16 121±6 (5) 9.03±0.15 93±5 (5) 8.83±0.23 91±6 (5) 
M367A 7.94±0.14 149±8* (4) 8.71±0.16 123±6* (6) 8.29±0.23 101±8 (5) 
L368A 7.76±0.14* 115±7 (6) 8.79±0.14 97±4 (5) 8.00±0.24* 94±9 (5) 
G369A 7.97±0.17* 148±10* (5) 8.93±0.22 97±7 (5) 8.12±0.14 110±6 (5) 
K370A N.D. N.D.  N.D. N.D.  N.D. N.D.  
I371A 8.09±0.20 42±3* (7) 8.83±0.21 31±14* (6) 8.38±0.29 61±6* (5) 
Y372A 7.83±0.36 68±9* (5) 8.74±0.29 46±4* (7) 8.54±0.35 44±5* (5) 
D373A 7.75±0.26* 102±10 (5) 8.79±0.26 78±6 (5) 7.83±0.18* 46±3* (5) 
Y374A 7.65±0.20* 110±9 (5) 8.67±0.19* 102±6 (6) 7.91±0.15* 106±6 (5) 
V375A 8.34±0.17 104±6 (5) 8.72±0.21 87±5 (6) 8.93±0.16 100±5 (5) 
M376A 8.08±0.26 52±5* (4) 8.67±0.13 95±4 (4) 8.25±0.27 47±4* (5) 
 
For each receptor and ligand, data were fit to a three-parameter logistic equation to derive pEC50 (negative 
logarithm of the concentration of ligand that produces half the maximal response) and Emax (maximal 
response, as % of WT). All values are mean ± S.E.M. (independent “n” values are indicated within 
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parentheses). For each ligand, significance of changes in pEC50 and Emax were determined by comparison of 
mutants to the WT receptor in a one-way analysis of variance followed by Dunnett’s post-test (p<0.05 
represented by *). (N.D.) pEC50 or Emax not determined. 
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Table 4:   Effect of single alanine mutation in hCTR ECL2 or ECL3 on pERK signalling in response to CT-family 
peptides.  
 
hCT sCT pCT rAmy hαCGRP  
pEC50 
Emax (% 
WT) 
N pEC50 
Emax (% 
WT) 
N pEC50 
Emax (% 
WT) 
N pEC50 
Emax 
(% 
WT) 
N pEC50 
Emax 
(% 
WT) 
N 
WT 8.32±0.
09 
100.0±3 (3
4) 
8.62±0.
10 
100±3 (3
5) 
8.95±0.
08 
100±3 (3
2) 
7.19±0.
10 
100±
5 
(3
0) 
7.11±0.
11 
100±6 (3
0) 
I279
A 
8.09±0.
19 
143±10* (5) 8.22±0.
11 
126±5* (5) 8.66±0.
17 
122±7 (5) 7.74±0.
27 
88±9 (5) 7.30±0.
23 
97±11 (5) 
T280
A 
8.17±0.
19 
168±12* (6) 8.55±0.
25 
158±12* (6) 8.69±0.
19 
160±10* (6) 7.57±0.
23 
110±
11 
(6) 7.27±0.
23 
106±1
2 
(6) 
R281
A 
N.D. N.D.  9.01±0.
43 
45±5* (5) 8.64±0.
35 
37±4* (5) 7.16±0.
27 
31±5
* 
(5) 7.46±0.
43 
30±5* (5) 
V283
A 
8.00±0.
24 
155±14* (5) 8.30±0.
22 
133±10* (6) 8.65±0.
34 
109±12 (5) 7.77±0.
27 
83±9 (5) 7.22±0.
18 
81±7 (4) 
Y284
A 
8.08±0.
23 
82±7 (5) 8.83±0.
21 
96±6 (5) 8.92±0.
25 
81±6 (5) 7.69±0.
23 
64±6
* 
(5) 6.95±0.
31 
79±15 (5) 
F285
A 
8.09±0.
33 
91±11 (5) 8.78±0.
16 
114±6 (5) 8.74±0.
20 
88±5 (5) 7.66±0.
28 
60±7
* 
(5) 6.90±0.
34 
93±18 (5) 
N286
A 
8.37±0.
32 
52±5* (5) 9.16±0.
28 
59±5* (5) 8.92±0.
36 
46±5* (5) 7.27±0.
32 
41±6
* 
(5) 7.89±0.
47 
31±5* (5) 
D287
A 
7.01±0.
25* 
35±5* (5) 9.40±0.
23 
39±2* (5) 7.9±0.2
5* 
27±3* (5) N.D. N.D.  N.D. N.D.  
N288
A 
7.74±0.
15 
137±8* (5) 8.36±0.
29 
127±13* (5) 8.53±0.
26 
135±11* (5) 7.28±0.
2 
79±7 (5) 7.01±0.
16 
110±1
0 
(5) 
C289
A 
7.10±0.
39* 
40±8* (5) 9.07±0.
57 
64±11* (5) 8.37±0.
28 
38±4* (5) N.D. N.D.  N.D. N.D.  
W29
0A 
N.D. N.D.  9.47±0.
41 
38±4* (5) 8.13±0.
26 
28±3* (5) N.D. N.D.  N.D. N.D.  
L291
A 
7.05±0.
24* 
72±9 (5) 8.61±0.
15 
107±5 (5) 8.02±0.
18* 
77±5 (5) 7.35±0.
22 
41±4
* 
(5) N.D. N.D.  
S292
A 
8.02±0.
26 
116±11 (5) 8.84±0.
21 
121±7 (5) 9.26±0.
25 
104±7 (5) 7.76±0.
31 
96±1
2 
(6) 7.68±0.
35 
80±12 (5) 
V293
A 
7.78±0.
15 
130±8* (5) 8.18±0.
24 
135±12* (5) 8.50±0.
25 
136±11* (5) 7.29±0.
26 
67±8
* 
(5) 7.28±0.
31 
149±2
2 
(5) 
E294
A 
8.07±0.
21 
125±10 (5) 8.67±0.
17 
126±7* (5) 8.70±0.
24 
115±9 (5) 7.43±0.
22 
72±7 (5) 6.91±0.
36 
66±15 (5) 
T295
A 
8.13±0.
34 
48±6* (5) 9.27±0.
30 
49±4* (5) 9.12±0.
32 
50±5* (5) 7.35±0.
39 
28±5
* 
(5) 7.68±0.
38 
22±4* (5) 
H296
A 
8.02±0.
14 
148±8* (5) 8.57±0.
20 
152±9* (5) 8.63±0.
20 
163±10* (6) 7.47±0.
22 
82±8 (5) 7.04±0.
27 
77±11 (5) 
L297
A 
8.10±0.
22 
63±5* (5) 9.05±0.
22 
68±4* (5) 9.01±0.
26 
59±4* (5) 7.55±0.
27 
49±6
* 
(5) 7.01±0.
29 
73±12 (5) 
L298
A 
7.82±0.
29 
84±10 (5) 8.75±0.
21 
85±6 (5) 8.96±0.
28 
73±6* (5) 7.69±0.
20 
82±7 (5) 7.12±0.
24 
58±8 (5) 
Y299
A 
7.99±0.
28 
56±6* (5) 9.23±0.
25 
58±4* (5) 9.03±0.
19 
51±3* (5) 7.22±0.
28 
51±7
* 
(5) N.D N.D  
I300
A 
8.71±0.
29 
65±6* (5) 9.49±0.
21 
63±3* (5) 9.55±0.
22 
54±3* (5) 7.48±0.
25 
44±5
* 
(5) 7.17±0.
42 
61±13 (5) 
F356
A 
7.77±0.
17* 
43±3* (4) 9.52±0.
25* 
72±5* (5) 8.35±0.
30 
57±6* (4) 7.06±0.
23 
41±5
* 
(5) 6.74±0.
28 
68±11 (5) 
V357
A 
7.92±0.
21 
53±5* (4) 8.61±0.
27 
82±7* (5) 8.43±0.
36 
83±10 (4) 7.46±0.
46 
40±8
* 
(5) N.D. N.D.  
V358
A 
7.83±0.
15* 
160±10* (5) 8.68±0.
16 
150±8* (4) 8.65±0.
26 
101±8 (4) 7.23±0.
35 
59±1
0* 
(5) 7.49±0.
50 
39±8* (5) 
F359
A 
7.57±0.
12* 
153±8* (5) 8.62±0.
12 
186±7* (5) 8.20±0.
15 
116±6 (5) 7.22±0.
4 
58±1
1* 
(5) 8.20±0.
15 
116±6 (5) 
P360
A 
7.12±0.
24* 
51±6* (5) 7.78±0.
19* 
115±9 (5) 7.40±0.
28* 
59±7* (5) N.D. N.D.  N.D. N.D.  
W36
1A 
7.64±0.
12* 
112±6 (5) 8.52±0.
12 
125±5* (4) 8.20±0.
22 
76±6* (5) 7.24±0.
49 
42±9
* 
(4) 6.93±0.
31 
49±8* (5) 
R362
A 
7.68±0.
25* 
64±7* (5) 8.81±0.
28 
107±10 (4) 8.12±0.
20 
45±4* (5) 6.94±0.
36 
36±7
* 
(4) 6.95±0.
61 
31±8* (5) 
P363
A 
7.59±0.
23* 
64±6* (5) 8.81±0.
15 
95±5 (4) 8.24±0.
15 
39±2* (5) 7.51±0.
81 
28±9
* 
(4) N.D. N.D.  
S364
A 
8.18±0.
20 
135±10* (5) 8.56±0.
13 
106±4 (4) 8.44±0.
28 
127±12* (4) 7.94±0.
36 
66±9
* 
(4) 7.97±0.
29 
54±6* (4) 
N365
A 
8.15±0.
16 
93±6 (5) 8.82±0.
12 
84±3 (4) 8.79±0.
32 
98±10 (5) 7.73±0.
39 
63±1
0* 
(5) 7.52±0.
39 
52±8* (4) 
K366
A 
8.33±0.
24 
186±16* (5) 8.84±0.
11 
136±5* (4) 8.72±0.
18 
156±9* (5) 7.89±0.
33 
84±1
1 
(5) 7.39±0.
27 
146±1
7* 
(4) 
M36
7A 
8.26±0.
15 
127±7* (5) 8.66±0.
10 
130±4* (4) 8.56±0.
19 
172±10* (5) 7.19±0.
15 
77±5 (5) 6.97±0.
27 
78±12 (4) 
L368
A 
8.05±0.
14 
126±7* (4) 8.62±0.
12 
140±6* (4) 8.71±0.
23 
159±11* (5) 7.56±0.
23 
82±8 (4) 7.07±0.
37 
84±16 (4) 
G369
A 
8.20±0.
18 
141±9* (5) 8.53±0.
11 
115±4 (4) 8.28±0.
18 
128±8* (5) 7.73±0.
34 
63±8
* 
(4) 7.09±0.
30 
87±14 (4) 
K370
A 
N.D. N.D.  N.D. N.D.  N.D. N.D.  N.D. N.D.  N.D. N.D.  
I371
A 
N.D. N.D.  N.D. N.D.  N.D. N.D.  N.D. N.D.  N.D. N.D.  
Y372
A 
8.74±0.
29 
46±4* (5) 8.64±0.
26 
39±3* (4) 7.72±0.
41* 
26±4* (4) N.D. N.D.  N.D. N.D.  
D373
A 
7.63±0.
24* 
71±7* (5) 8.62±0.
34 
103±11 (4) 8.31±0.
35 
32±4* (5) N.D. N.D.  N.D. N.D.  
Y374
A 
7.92±0.
09 
94±4 (5) 8.63±0.
14 
99±5 (4) 8.57±0.
24 
105±8 (4) 7.21±0.
17 
61±5
* 
(4) 7.21±0.
31 
49±8* (5) 
V375
A 
8.08±0.
13 
67±3* (4) 8.83±0.
14 
70±3* (5) 8.58±0.
14 
89±4 (5) 6.91±0.
29 
77±1
3 
(5) 6.96±0.
24 
58±7* (5) 
M37
6A 
7.58±0.
21* 
52±4* (4) 8.35±0.
2 
72±5* (4) 8.71±0.
29 
47±4* (5) 7.17±0.
32 
43±7
* 
(5) 7.74±0.
60 
36±8* (5) 
 
For each receptor and ligand, data were fit to a three-parameter logistic equation to derive pEC50 (negative 
logarithm of the concentration of ligand that produces half the maximal response) and Emax (maximal 
  
 49 
response, as % of WT). All values are mean ± S.E.M. (independent “n” values are indicated within parentheses). 
For each ligand, significance of changes in pEC50 and Emax were determined by comparison of mutants to the 
WT receptor in a one-way analysis of variance followed by Dunnett’s post-test (p<0.05 represented by *). (N.D.) 
pEC50 or Emax not determined. 
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Table 5.     Effect of single alanine mutation in hCTR ECL2 or ECL3 on functional affinities of 
CT-family peptides.  
 
hCT sCT pCT rAmy hαCGRP 
cAMP  IP1  pERK1/2  cAMP  IP1  pERK1/2  cAMP  IP1  pERK1/2  cAMP pERK1/2 cAMP pERK1/2 
WT 
9.54±0.09 
(36) 
8.54±0.10 
(47) 
8.15±0.0
8 (34) 
10.5±0.09 (36) 9.2±0.12 (44) 8.55±0.07 (35) 
10.1±0.10 
(31) 
8.75±0.13 
(37) 
8.74±0.09 
(32) 
7.72±0.11 
(31) 
7.23±0.11 
(30) 
7.69±0.16 
(25) 
7.10±0.1
1 (30) 
I279A 
10.0±0.32 
(4) 
7.89±0.16 (7) 
7.68±0.1
6 (5) 
10.8±0.32 (5) 8.54±0.19 (7) 7.89±0.19 (5) 10.1±0.26 (6) 
7.82±0.22* 
(5) 
8.39±0.18 (5) 
8.30±0.25 
(5) 
7.58±0.19 
(5) 
7.99±0.12 
(5) 
7.03±0.2
4 (5) 
T280A 
10.0±0.35 
(4) 
7.56±0.18* 
(6) 
7.59±0.1
4 (6) 
11.0±0.35 (4) 8.49±0.13 (7) 8.04±0.15 (6) 9.96±0.26 (5) 8.35±0.21 (7) 8.15±0.14 (6) 
8.32±0.25 
(5) 
7.27±0.15 
(6) 
7.92±0.24 
(5) 
6.95±0.2
0 (6) 
R281A 
6.74±0.34* 
(8) 
7.84±0.50 (7) N.D. 9.89±0.21 (11) 9.24±0.20 (6) 8.97±0.11 (5) 
8.30±0.15* 
(6) 
8.47±0.18 (6) 8.57±0.12 (5) 
7.12±0.12 
(5) 
7.01±0.58 
(5) 
6.89±0.16 
(5) 
7.71±0.2
2 (5) 
V283A 
10.2±0.35 
(4) 
7.43±0.22* 
(5) 
7.55±0.1
5 (5) 
10.7±0.28 (5) 8.63±0.14 (7) 7.97±0.17 (6) 10.1±0.27 (5) 7.94±0.21 (7) 8.38±0.20 (5) 
8.03±0.17 
(5) 
7.59±0.19 
(5) 
7.49±0.17 
(5) 
7.18±0.3
1 (4) 
Y284A 
9.77±0.29 
(5) 
7.92±0.24 (7) 
7.93±0.2
5 (5) 
10.6±0.28 (5) 8.51±0.15 (6) 8.60±0.23 (5) 9.85±0.25 (6) 8.64±0.21 (7) 8.73±0.25 (5) 
7.61±0.30 
(5) 
7.55±0.25 
(5) 
7.20±0.32 
(5) 
6.69±0.3
0 (5) 
F285A 
9.65±0.29 
(5) 
7.98±0.24 (6) 
7.93±0.2
3 (5) 
10.7±0.29 (5) 8.30±0.17* (5) 8.48±0.20 (5) 10.1±0.30 (6) 7.93±0.21 (6) 8.54±0.23 (5) 
7.89±0.31 
(5) 
7.47±0.28 
(5) 
7.46±0.28 
(5) 
6.76±0.2
6 (5) 
N286A 
8.81±0.30 
(5) 
8.56±0.32 (6) 
8.16±0.4
1 (5) 
10.4±0.30 (5) 8.71±0.27 (6) 8.99±0.37 (5) 9.43±0.32 (5) 9.02±0.26 (7) 8.75±0.26 (5) 
7.05±0.27 
(5) 
7.16±0.44 
(5) 
7.65±0.23 
(5) 
8.25±0.2
9* (5) 
D287A 
6.81±0.32* 
(6) 
N.D. 
6.71±0.2
4* (5) 
9.79±0.22* (10) N.D. 9.09±0.30 (5) 
8.52±0.42* 
(6) 
8.33±0.17 (6) 
7.65±0.30* 
(5) 
N.D. N.D. N.D. N.D. 
N288A 
9.52±0.27 
(5) 
7.58±0.16* 
(7) 
7.35±0.1
7* (6) 
10.8±0.29 (6) 8.45±0.19 (6) 7.98±0.18 (5) 9.79±0.27 (5) 8.56±0.21 (7) 8.11±0.16 (6) 
8.40±0.23 
(5) 
-7.15±0.24 
(5) 
7.55±0.18 
(5) 
6.74±0.2
2 (5) 
C289A 
7.02±0.33* 
(8) 
N.D. 
6.84±0.3
6* (5) 
9.57±0.3* (10) 8.31±0.39* (6) 8.92±0.34 (5) 
8.50±0.35* 
(8) 
N.D. 8.13±0.30 (5) 
6.77±0.15* 
(5) 
N.D. N.D. N.D. 
W290A N.D. N.D. N.D. 9.45±0.34* (11) N.D. 9.03±0.43 (5) 
8.08±0.31* 
(5) 
N.D. 
7.84±0.35* 
(5) 
6.55±0.32* 
(5) 
N.D. N.D. N.D. 
L291A 
7.69±0.27* 
(10) 
6.35±0.4* (7) 
6.83±0.3
6* (5) 
10.4±0.23 (10) 8.47±0.21 (7) 8.36±0.21 (5) 
9.05±0.27* 
(6) 
8.67±0.30 (7) 
7.82±0.28* 
(5) 
7.29±0.23 
(5) 
7.21±0.43 
(5) 
6.67±0.24* 
(5) 
N.D. 
S292A 
9.24±0.2
9 (6) 
7.23±0.25* 
(6) 
7.82±0.1
8 (5) 
10.6±0.28 (6) 8.57±0.19 (7) 8.58±0.18 (5) 9.87±0.26 (6) 8.13±0.20 (7) 9.15±0.20 (5) 
8.05±0.28 
(6) 
7.55±0.16 
(6) 
7.20±0.15 
(5) 
7.47±0.2
5 (5) 
V293A 
9.58±0.28 
(5) 
8.01±0.15 (7) 
7.41±0.1
8 (5) 
10.4±0.28 (5) 8.92±0.16 (7) .74±0.18* (5) 9.95±0.25 (6) 8.19±0.22 (7) 8.13±0.17 (5) 
7.84±0.29 
(6) 
7.12±0.28 
(5) 
7.41±0.17 
(5) 
6.79±0.1
9 (5) 
E294A 
9.84±0.29 
(5) 
8.05±0.21 (6) 
7.74±0.1
7 (5) 
10.7±0.30 (5) 8.36±0.24* (6) 8.32±0.19 (5) 10.0±0.27 (5) 8.62±0.17 (6) 8.42±0.18 (5) 
7.61±0.32 
(5) 
7.24±0.25 
(5) 
6.88±0.35 
(5) 
6.64±0.3
6 (5) 
T295A 
8.83±0.30 
(5) 
7.76±0.32 (6) 
7.97±0.4
4 (5) 
9.60±0.31 (5) 8.22±0.34* (6) 9.05±0.15 (5) 
8.98±0.28* 
(5) 
8.15±0.41 (6) 8.96±0.41 (5) 
7.00±0.17 
(5) 
N.D. 
6.71±0.21* 
(5) 
7.61±0.2
4 (5) 
H296A 
10.1±0.25 
(10) 
7.83±0.18 (7) 
7.59±0.1
6 (5) 
10.6±0.24 (10) 9.08±0.18 (7) 8.13±0.17 (5) 10.1±0.29 (5) 8.07±0.23 (6) 8.08±0.14 (6) 
7.87±0.29 
(5) 
7.30±0.22 
(5) 
7.48±0.16 
(6) 
6.91±0.2
9 (5) 
L297A 
9.37±0.27 
(4) 
7.40±0.31* 
(7) 
7.99±0.3
3 (5) 
10.4±0.33 (4) 8.89±0.27 (6) 8.90±0.22 (5) 9.44±0.25 (6) 8.54±0.30 (7) 8.91±0.35 (5) 
7.59±0.24 
(5) 
7.43±0.35 
(5) 
7.14±0.12 
(5) 
6.82±0.3
1 (5) 
L298A 
9.07±0.31 
(5) 
7.58±0.25* 
(7) 
7.62±0.2
5 (6) 
10.2±0.29 (5) 8.72±0.24 (7) 8.54±0.26 (5) 9.70±0.26 (5) 8.09±0.25 (5) 8.78±0.27 (5) 
7.77±0.28 
(5) 
7.49±0.20 
(5) 
7.10±0.30 
(5) 
6.95±0.3
7 (5) 
Y299A 
8.68±0.32 
(5) 
7.97±0.46 (6) 
7.81±0.3
8 (5) 
10.4±0.31 (5) 8.04±0.36* (6) 9.05±0.38 (5) 9.35±0.24 (6) 9.20±0.40 (7) 8.85±0.40 (5) 
7.36±0.10 
(4) 
-7.15±0.36 
(5) 
7.32±0.19 
(5) 
N.D. 
I300A 
9.31±0.28 
(5) 
7.97±0.32 (7) 
8.55±0.3
1 (5) 
10.2±0.29 (5) N.D. 9.29±0.36* (5) 9.72±0.26 (5) N.D. 9.29±0.31 (5) 
7.18±0.33 
(5) 
7.38±0.40 
(5) 
7.54±0.24 
(5) 
7.03±0.3
5 (5) 
F356A 
8.05±0.35* 
(5) 
7.70±0.30 (6) 
7.58±0.2
7 (4) 
9.73±0.21 (6) 9.05±0.41 (6) 9.38±0.21* (5) 
8.85±0.29* 
(4) 
N.D. 8.23±0.33 (4) 
7.09±0.32 
(4) 
6.95±0.45 
(5) 
6.65±0.21* 
(5) 
6.65±0.3
4 (4) 
V357A 
8.43±0.25* 
(6) 
7.37±0.48* 
(5) 
7.74±0.2
6 (4) 
10.1±0.21 (6) 8.69±0.42 (5) 8.44±0.19 (5) 9.73±0.32 (4) 
7.69±0.40* 
(5) 
8.19±0.25 (4) 
7.36±0.33 
(5) 
7.29±0.44 
(5) 
7.29±0.15 
(5) 
N.D. 
V358A 
9.29±0.28 
(4) 
7.28±0.17* 
(6) 
7.31±0.1
3* (5) 
10.7±0.25 (4) 8.31±0.13* (6) 8.19±0.13 (4) 9.40±0.28 (4) 8.20±0.26 (5) 8.38±0.20 (4) 
7.50±0.33 
(4) 
7.06±0.30 
(5) 
7.42±0.27 
(5) 
7.34±0.5
0 (5) 
F359A 
8.50±0.21* 
(5) 
7.08±0.24* 
(5) 
7.07±0.1
5* (5) 
10.6±0.20 (5) 8.29±0.14* (5) 7.79±0.13* (5) 9.65±0.28 (4) 
7.68±0.24* 
(5) 
7.87±0.18* 
(5) 
7.33±0.31 
(5) 
7.10±0.31 
(4) 
7.49±0.19 
(5) 
6.64±0.2
9 (5) 
P360A 
7.96±0.34* 
(5) 
6.77±0.26* 
(5) 
6.98±0.4
0* (5) 
10.0±0.20 (5) 7.99±0.13* (6) 7.50±0.15* (5) 
9.03±0.27* 
(4) 
6.76±0.28* 
(5) 
7.31±0.22* 
(5) 
7.24±0.28 
(5) 
N.D. 
7.59±0.34 
(5) 
N.D. 
W361A 
8.69±0.23 
(5) 
7.55±0.23* 
(6) 
7.30±0.2
0* (5) 
10.4±0.21 (5) 8.66±0.15 (5) 8.16±0.15 (4) 9.10±0.31 (4) 
7.80±0.25* 
(6) 
7.99±0.27 (5) 
7.40±0.28 
(5) 
7.23±0.44 
(4) 
6.73±0.23* 
(5) 
6.90±0.3
8 (5) 
R362A 
8.22±0.24* 
(4) 
7.34±0.27* 
(6) 
7.49±0.2
9 (5) 
9.85±0.23 (4) 8.51±0.25 (5) 8.53±0.16 (4) 
8.45±0.32* 
(4) 
7.68±0.42* 
(6) 
7.91±0.25* 
(5) 
7.27±0.38 
(4) 
6.78±0.54 
(4) 
7.62±0.10 
(5) 
7.01±0.6
1 (5) 
P363A 
8.29±0.25* 
(5) 
N.D. 
7.38±0.3
0 (5) 
10.4±0.20 (5) 9.04±0.19 (5) 8.57±0.18 (4) 
8.68±0.30* 
(4) 
8.08±0.25 (6) 8.05±0.25 (5) 
7.48±0.27 
(6) 
7.43±0.63 
(4) 
7.25±0.16 
(5) 
N.D. 
S364A 
9.56±0.21 
(5) 
7.47±0.22* 
(5) 
7.82±0.1
4 (5) 
10.5±0.21 (5) 8.56±0.18 (5) 8.23±0.17 (4) 10.2±0.35 (4) 
-8.00±0.20 
(5) 
8.11±0.17 (4) 
8.18±0.33 
(4) 
7.76±0.23 
(4) 
7.53±0.31 
(4) 
7.75±0.3
0 (4) 
N365A 
9.55±0.22 
(5) 
8.08±0.28 (5) 
7.93±0.1
8 (5) 
10.6±0.24 (5) 8.71±0.26 (4) 8.57±0.20 (4) 10.4±0.27 (4) 8.49±0.31 (5) 8.58±0.18 (5) 
7.93±0.30 
(4) 
7.56±0.26 
(5) 
7.41±0.15 
(5) 
7.30±0.3
6 (4) 
K366A 
9.84±0.31 
(5) 
8.20±0.17 (5) 
7.52±0.1
4 (5) 
10.6±0.24 (5) 8.73±0.17 (5) 8.41±0.13 (4) 10.5±0.29 (4) 8.68±0.21 (5) 8.17±0.13 (5) 
7.83±0.20 
(4) 
7.66±0.17 
(5) 
8.02±0.34 
(5) 
6.89±0.1
6 (4) 
M367A 
9.49±0.34 
(5) 
7.50±0.17* 
(5) 
7.91±0.1
4 (5) 
10.8±0.25 (5) 8.27±0.13* (6) 8.28±0.14 (4) 10.2±0.31 (4) 8.02±0.19 (5) 
7.93±0.14* 
(5) 
8.09±0.23 
(4) 
7.04±0.24 
(5) 
7.27±0.23 
(5) 
6.77±0.2
7 (4) 
L368A 
9.85±0.32 
(5) 
7.41±0.17* 
(6) 
7.68±0.1
6 (4) 
10.4±0.20 (5) 8.51±0.17 (5) 8.21±0.13 (4) 9.63±0.33 (4) 
7.66±0.22* 
(5) 
8.21±0.14 (5) 
7.61±0.28 
(5) 
7.35±0.21 
(4) 
7.67±0.32 
(5) 
6.94±0.2
4 (4) 
G369A 
9.31±0.22 
(5) 
7.28±0.21* 
(5) 
7.78±0.1
3 (5) 
10.4±0.24 (5) 8.61±0.16 (5) 8.22±0.16 (4) 9.97±0.30 (4) 7.80±0.19 (5) 
7.90±0.17* 
(5) 
7.56±0.28 
(4) 
7.55±0.26 
(4) 
7.06±0.25 
(5) 
6.84±0.2
3 (4) 
K370A N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
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I371A 
9.63±0.33 
(5) 
8.07±0.22 (5) N.D. 10.8±0.21 (5) 8.45±0.19 (6) N.D. 10±0.30 (4) 8.58±0.19 (5) N.D. 
8.29±0.26 
(5) 
N.D. 
7.02±0.34 
(5) 
N.D. 
Y372A 
7.18±0.35* 
(4) 
7.67±0.35 (5) 
6.76±0.3
0* (5) 
9.60±0.22 (4) 8.81±0.43 (5) 8.55±0.42 (5) 
8.23±0.35* 
(4) 
8.27±0.34 (5) 
7.57±0.28* 
(4) 
N.D. N.D. 
6.93±0.25 
(5) 
N.D. 
D373A 
8.41±0.27* 
(4) 
7.51±0.20* 
(5) 
7.41±0.2
7 (5) 
10.3±0.21 (4) 8.60±0.22 (5) 8.34±0.15 (4) 
8.39±0.34* 
(4) 
7.59±0.28* 
(5) 
8.09±0.28 (4) 
7.81±0.29 
(5) 
N.D. 
7.72±0.24 
(5) 
N.D. 
Y374A 
9.45±0.28 
(5) 
7.32±0.20* 
(5) 
7.67±0.1
8 (5) 
10.5±0.20 (5) 8.34±0.15* (6) 8.36±0.18 (4) 10.4±0.32 (4) 
7.60±0.18* 
(5) 
8.35±0.20 (4) 
7.75±0.33 
(4) 
7.12±0.3 
(4) 
7.35±0.34 
(5) 
7.07±0.3
7 (5) 
V375A 
9.21±0.20 
(5) 
7.98±0.28 (5) 
7.88±0.2
8 (4) 
10.2±0.20 (5) 8.32±0.22* (6) 8.70±0.23 (5) 9.59±0.41 (4) 8.25±0.31 (5) 8.32±0.23 (5) 
7.79±0.29 
(5) 
6.70±0.26 
(4) 
7.27±0.26 
(5) 
6.78±0.4
0 (5) 
M376A 
8.12±0.31* 
(5) 
7.83±0.41 (4) 
7.47±0.2
1 (4) 
10.2±0.21 (5) 8.43±0.19 (4) 8.17±0.25 (4) 9.30±0.36 (4) 7.90±0.30 (5) 8.54±0.14 (5) 
7.09±0.27 
(5) 
7.09±0.43 
(5) 
6.63±0.31* 
(6) 
7.52±0.2
6 (5) 
 
For each receptor mutant and ligand, concentration-response data for each pathway were fit with the Black 
and Leff operational model to derive a functional affinity (pKA) for each pathway. All values are mean ± S.E.M. 
(independent “n” values are indicated within parentheses). For each ligand, significance of changes was 
determined by comparison of mutant receptor pKA to WT receptor pKA in a one-way analysis of variance 
followed by Dunnett’s post-test (p<0.05 represented by *). (N.D.) data were not able to be reliably 
determined. WT pKA values for sCT were 10.52±0.09, 9.20±0.12, and 8.55±0.07, for cAMP, IP1 and pERK 
signalling, respectively. The corresponding values for hCT were 9.54±0.09, 8.54±0.10, and 8.15±0.08, and for 
pCT were 10.12±0.10, 8.75±0.13 and 8.74±0.09. pKA values for cAMP and pERK were, respectively, 7.50±0.33 
and 7.23±0.11 for rAmy, and 7.69±0.16 and 7.10±0.11 for CGRP. 
 
 
 
 
 
 
Table 6. Effect of single alanine mutation in hCTR ECL2 or ECL3 on efficacy of CT-family 
peptides.  
 
hCT sCT pCT rAmy hαCGRP 
cAMP IP1 pERK1/2 cAMP IP1 pERK1/2 cAMP IP1 pERK1/2 cAMP pERK1/2 cAMP pERK1/2 
WT 
0.18±0.0
7 (36) 
-0.07±0.02 
(47) 
-0.11±0.04 
(34) 
0.25±0.12 
(36) 
-0.04±0.02 
(44) 
-
0.15±0.
02 (35) 
0.12±0.10 
(31) 
-0.07±0.04 
(37) 
-0.11±0.03 
(32) 
0.12±0.0
9 (31) 
-0.10±0.03 
(30) 
0.11±0.0
9 (25) 
-0.08±0.08 
(30) 
I279A 
-
0.09±0.
10 (4) 
-0 .30±0.10 
(7) 
0.20±0.09 
(5) 
0.00±0.13 
(5) 
-0.13±0.10 
(7) 
0.05±0.
09 (5) 
0.07±0.12 
(6) 
0.01±0.10 
(5) 
0.02±0.08 
(5) 
-
0.11±0.1
2 (5) 
-0.24±0.15 
(5) 
0.37±0.2
2 (5) 
-0.14±0.11 
(5) 
T280A 
-
0.13±0.
10 (4) 
-0.39±0.11 
(6) 
0.35±0.11 
(6) 
0.06±0.16 
(4) 
-0.01±0.11 
(7) 
0.24±0.
10 (6) 
0.14±0.15 
(5) 
-0.22±0.10 
(7) 
0.27±0.10 
(6) 
-
0.34±0.1
3 (4) 
-0.15±0.14 
(6) 
-
0.01±0.2
0 (5) 
-0.17±0.11 
(6) 
R281A 
0.74±0.1
7* (8) 
-0.33±0.14 
(7) 
N.D. 
0.87±0.17* 
(11) 
0.37±0.14 
(6) 
-
0.16±0.
16 (5) 
1.31±0.34* 
(6) 
-0.02±0.15 
(6) 
-0.27±0.17 
(5) 
0.26±0.1
8 (5) 
-0.29±0.16 
(5) 
0.71±0.2
4 (5) 
-0.30±0.19 
(5) 
V283A 
-
0.01±0.
10 (4) 
-0.32±0.13 
(5) 
0.40±0.14 
(5) 
0.36±0.17 
(5) 
0.11±0.13 
(7) 
0.20±0.
13 (6) 
0.26±0.14 
(5) 
-0.04±0.13 
(7) 
0.00±0.13 
(5) 
-
0.07±0.1
3 (5) 
-0.19±0.15 
(5) 
0.36±0.2
5 (5) 
-0.21±0.15 
(4) 
Y284A 
0.22±0.1
0 (5) 
-0.33±0.13 
(7) 
-0.12±0.14 
(5) 
0.42±0.16 
(5) 
0.25±0.13 
(6) 
0.01±0.
13 (5) 
0.33±0.13 
(6) 
0.03±0.13 
(7) 
-0.12±0.13 
(5) 
0.30±0.1
5 (5) 
-0.24±0.32 
(5) 
0.57±0.2
8 (5) 
-0.09±0.16 
(5) 
F285A 
0.12±0.1
0 (5) 
-0.47±0.17 
(6) 
-0.17±0.17 
(5) 
0.23±0.15 
(5) 
0.09±0.17 
(5) 
0.03±0.
17 (5) 
-0.02±0.11 
(6) 
0.05±0.18 
(6) 
-0.18±0.17 
(5) 
0.08±0.1
4 (5) 
-0.42±0.20 
(5) 
0.27±0.2
1 (5) 
-0.12±0.19 
(5) 
N286A 
0.92±0.1
4* (5) 
-0.07±0.17 
(6) 
0.03±0.18 
(5) 
0.78±0.15 
(5) 
0.17±0.17 
(5) 
0.10±0.
18 (5) 
0.58±0.12 
(5) 
0.30±0.17 
(7) 
-0.04±0.18 
(5) 
0.69±0.1
8* (5) 
-0.07±0.24 
(5) 
0.13±0.2
1 (5) 
-0.20±0.20 
(5) 
D287A 
1.46±0.3
4* (6) 
N.D. 
0.08±0.33 
(5) 
1.25±0.17* 
(10) 
N.D. 
0.12±0.
21 (5) 
0.70±0.14 
(6) 
0.78±0.20* 
(6) 
-0.10±0.29 
(5) 
N.D. N.D. N.D. N.D. 
N288A 
0.11±0.1
2 (5) 
-0.26±0.13 
(7) 
0.08±0.15 
(5) 
-0.23±0.11 
(6) 
-0.11±0.13 
(6) 
0.00±0.
14 (5) 
0.09±0.14 
(5) 
-0.25±0.14 
(7) 
0.07±0.14 
(5) 
-
0.36±0.1
2 (5) 
-0.38±0.14 
(5) 
0.10±0.2
2 (5) 
-0.12±0.16 
(5) 
C289A 
0.80±0.2
8* (8) 
N.D. 
0.19±0.34 
(5) 
1.57±0.29* 
(10) 
0.27±0.27 
(6) 
0.46±0.
28* (5) 
1.22±0.20* 
(8) 
N.D. 
0.16±0.29 
(5) 
0.95±0.2
1* (5) 
N.D. N.D. N.D. 
W290A N.D. N.D. N.D. 
1.71±0.50* 
(11) 
N.D. 
-
0.04±0.
34 (5) 
1.01±0.18* 
(5) 
N.D. 
-0.20±0.37 
(5) 
0.64±0.2
5 (5) 
N.D. N.D. N.D. 
L291A 
0.36±0.1
4 (10) 
-0.39±0.15 
(7) 
-0.38±0.19 
(5) 
0.20±0.14 
(10) 
-0.21±0.15 
(7) 
-
0.08±0.
15 (5) 
0.17±0.14 
(6) 
-0.41±0.15 
(7) 
-0.34±0.16 
(5) 
0.13±0.1
6 (5) 
-
0.68±0.1
6* (5) 
0.09±0.2
0 (5) 
N.D. 
  
 52 
S292A 
0.56±0.1
5 (6) 
-0.28±0.19 
(6) 
0.13±0.19 
(5) 
0.48±0.18 
(6) 
-0.01±0.19 
(7) 
0.17±0.
19 (5) 
0.64±0.21 
(6) 
-0.04±0.19 
(7) 
0.03±0.19 
(5) 
0.20±0.1
3 (6) 
-0.01±0.19 
(6) 
0.23±0.2
1 (5) 
-0.12±0.20 
(5) 
V293A 
0.30±0.1
2 (5) 
-0.21±0.13 
(6) 
0.14±0.14 
(5) 
0.28±0.17 
(5) 
0.03±0.13 
(7) 
0.19±0.
14 (5) 
0.22±0.14 
(6) 
0.03±0.14 
(5) 
0.19±0.13 
(5) 
0.05±0.1
3 (6) 
-0.37±0.14 
(5) 
0.61±0.1
7 (5) 
0.33±0.15 
(5) 
E294A 
0.10±0.1
0 (5) 
-0.42±0.23 
(6) 
0.09±0.13 
(5) 
0.13±0.14 
(5) 
-0.20±0.23 
(6) 
0.10±0.
13 (5) 
0.19±0.14 
(5) 
0.04±0.13 
(6) 
0.01±0.13 
(5) 
0.02±0.1
4 (5) 
-0.32±0.12 
(5) 
0.38±0.1
8 (5) 
-0.35±0.18 
(5) 
T295A 
0.91±0.1
4* (5) 
-0.08±0.21 
(6) 
-0.05±0.23 
(5) 
1.20±0.21* 
(5) 
0.06±0.21 
(6) 
-
0.04±0.
22 (5) 
0.99±0.19* 
(5) 
0.08±0.23 
(6) 
-0.03±0.22 
(5) 
0.46±0.2
0 (5) 
N.D. 
0.44±0.2
7 (5) 
-0.37±0.27 
(5) 
H296A 
0.02±0.0
8 (10) 
-0.21±0.16 
(7) 
0.39±0.15 
(5) 
0.10±0.11 
(10) 
0.05±0.16 
(7) 
0.42±0.
15* (5) 
0.20±0.13 
(5) 
0.02±0.14 
(6) 
0.53±0.14* 
(6) 
0.30±0.1
5 (5) 
-0.14±0.08 
(5) 
0.21±0.1
8 (6) 
-0.18±0.16 
(5) 
L297A 
0.51±0.1
1 (4) 
0.04±0.12 
(7) 
0.09±0.13 
(5) 
0.72±0.15 
(4) 
0.22±0.12 
(6) 
0.14±0.
13 (5) 
1.01±0.19* 
(6) 
0.17±0.13 
(7) 
0.05±0.13 
(5) 
0.52±0.1
4 (5) 
-0.01±0.30 
(5) 
0.50±0.2
1 (5) 
0.25±0.15 
(5) 
L298A 
0.33±0.1
1 (5) 
-0.23±0.24 
(7) 
-0.01±0.24 
(5) 
0.52±0.17 
(5) 
-0.13±0.24 
(7) 
0.00±0.
24 (5) 
0.59±0.17 
(5) 
0.10±0.24 
(5) 
-0.10±0.24 
(5) 
0.56±0.1
7 (5) 
0.00±0.25 
(5) 
0.37±0.2
3 (5) 
-0.20±0.26 
(5) 
Y299A 
0.22±0.1
5 (5) 
-
0.96±0.3
1* (6) 
-
0.72±0.1
8* (5) 
0.07±0.16 
(5) 
-
0.68±0.3
9* (6) 
-
0.69±0.
28* (5) 
0.15±0.16 
(6) 
-
0.74±0.1
8* (7) 
-
0.76±0.1
8* (5) 
-
0.04±0.1
7 (4) 
-
0.73±0.1
7* (5) 
-
0.49±0.2
1 (5) 
N.D. 
I300A 
1.16±0.1
2* (5) 
0.33±0.10 
(7) 
0.53±0.12
* (5) 
1.24±0.17* 
(5) 
N.D. 
0.50±0.
12* (5) 
1.3±0.17* 
(5) 
N.D. 
0.41±0.13 
(5) 
1.19±0.1
8* (5) 
0.33±0.16 
(5) 
0.76±0.1
9* (5) 
0.54±0.15* 
(5) 
F356A 
1.05±0.1
9* (5) 
0.15±0.15 
(6) 
-0.10±0.17 
(4) 
1.08±0.17* 
(6) 
-0.16±0.14 
(6) 
0.20±0.
12 (5) 
1.49±0.10* 
(4) 
N.D. 
0.06±0.15 
(4) 
0.90±0.1
9* (4) 
-0.12±0.14 
(5) 
0.91±0.2
* (5) 
0.16±0.18 
(4) 
V357A 
0.59±0.2
1 (6) 
-0.55±0.18 
(5) 
-0.54±0.16 
(4) 
0.61±0.18 
(6) 
-
0.69±0.1
4* (5) 
-
0.27±0.
14 (5) 
0.62±0.28 
(4) 
-0.59±0.16 
(5) 
-0.25±0.15 
(4) 
-
0.05±0.1
3 (5) 
-
0.69±0.1
4* (5) 
-
0.12±0.1
3 (5) 
N.D. 
V358A 
0.10±0.1
0 (4) 
0.12±0.19 
(6) 
0.41±0.19 
(5) 
-0.04±0.09 
(4) 
0.18±0.18 
(6) 
0.31±0.
18 (4) 
0.25±0.27 
(4) 
-0.32±0.19 
(5) 
-0.10±0.19 
(4) 
0.02±0.1
4 (4) 
-0.45±0.24 
(5) 
-
0.20±0.1
2 (5) 
-
0.72±0.2
2* (5) 
F359A 
0.28±0.1
6 (5) 
-0.28±0.20 
(5) 
0.15±0.19 
(5) 
-0.06±0.09 
(5) 
0.01±0.19 
(5) 
0.55±0.
20* (5) 
0.14±0.16 
(4) 
-0.46±0.19 
(5) 
-0.16±0.19 
(5) 
-
0.17±0.1
3 (5) 
-0.66±0.19 
(4) 
-
0.60±0.1
4* (5) 
-
1.08±0.3
1* (5) 
P360A 
0.38±0.2
3 (5) 
-
0.62±0.1
5* (5) 
-
1.06±0.1
6* (5) 
-0.06±0.14 
(5) 
-0.10±0.12 
(6) 
-
0.48±0.
12 (5) 
1.07±0.17* 
(4) 
-0.47±0.17 
(5) 
-
0.98±0.1
6* (5) 
-
0.28±0.1
5 (5) 
N.D. 
-
0.98±0.1
4* (5) 
N.D. 
W361A 
0.38±0.1
8 (5) 
-0.32±0.17 
(6) 
-0.14±0.17 
(5) 
-0.05±0.09 
(5) 
-0.08±0.17 
(5) 
-
0.03±0.
17 (4) 
0.4±0.24 
(4) 
-0.36±0.17 
(6) 
-0.44±0.17 
(5) 
-
0.04±0.1
3 (5) 
-
0.80±0.1
8* (4) 
-
0.07±0.1
6 (5) 
-
0.74±0.2
0* (5) 
R362A 
0.56±0.1
5 (4) 
-0.15±0.15 
(6) 
-0.26±0.15 
(5) 
0.40±0.12 
(4) 
-0.20±0.14 
(5) 
0.11±0.
13 (4) 
0.87±0.27* 
(4) 
-0.44±0.16 
(6) 
-0.48±0.16 
(5) 
0.12±0.1
5 (4) 
-0.58±0.18 
(4) 
-
0.30±0.1
4 (5) 
-
0.71±0.2
1* (5) 
P363A 
0.34±0.1
3 (5) 
N.D. 
-0.32±0.12 
(5) 
0.26±0.10 
(5) 
- 0.05±0.12 
(5) 
-
0.05±0.
1 (4) 
1.47±0.35* 
(4) 
-0.21±0.11 
(6) 
-0.63±0.14 
(5) 
0.11±0.1
2 (6) 
-
0.77±0.0
8* (4) 
-
0.52±0.2
1 (5) 
N.D. 
S364A 
0.16±0.0
9 (5) 
-0.08±0.19 
(5) 
0.24±0.19 
(5) 
0.13±0.09 
(5) 
-0.08±0.19 
(5) 
0.01±0.
19 (4) 
0.09±0.14 
(4) 
-0.08±0.19 
(5) 
0.17±0.19 
(4) 
-
0.31±0.1
2 (4) 
-0.33±0.20 
(4) 
-
0.04±0.1
2 (4) 
-0.46±0.20 
(4) 
N365A 
0.03±0.1
0 (5) 
-0.33±0.13 
(5) 
-0.21±0.12 
(5) 
-0.12±0.08 
(5) 
-0.39±0.15 
(4) 
-
0.29±0.
12 (4) 
-0.16±0.13 
(4) 
-0.44±0.13 
(5) 
-0.18±0.12 
(5) 
-
0.25±0.1
3 (4) 
-0.47±0.29 
(5) 
0.11±0.1
3 (5) 
-0.59±0.14 
(4) 
K366A 
-
0.21±0.
09 (5) 
0.02±0.13 
(5) 
0.67±0.15
* (5) 
-0.16±0.08 
(5) 
-0.15±0.23 
(5) 
0.13±0.
13 (4) 
-0.24±0.11 
(4) 
-0.22±0.13 
(5) 
0.32±0.13 
(5) 
-
0.28±0.1
3 (4) 
-0.29±0.35 
(5) 
-
0.27±0.1
1 (5) 
0.22±0.14 
(4) 
M367A 
-
0.03±0.
09 (5) 
0.36±0.15 
(4) 
0.15±0.13 
(5) 
-0.10±0.08 
(5) 
0.22±0.13 
(6) 
0.17±0.
13 (4) 
0.11±0.12 
(4) 
-0.03±0.14 
(5) 
0.58±0.14* 
(5) 
0.04±0.1
2 (4) 
-0.26±0.17 
(5) 
0.23±0.1
3 (5) 
-0.25±0.16 
(4) 
L368A 
-
0.13±0.
09 (5) 
0.10±0.12 
(6) 
0.17±0.12 
(4) 
0.25±0.10 
(5) 
0.00±0.12 
(5) 
0.28±0.
12 (4) 
0.04±0.13 
(4) 
-0.06±0.13 
(5) 
0.46±0.12* 
(5) 
0.09±0.1
2 (5) 
-0.18±0.12 
(4) 
-
0.09±0.1
1 (5) 
-0.19±0.14 
(4) 
G369A 
0.36±0.1
7 (5) 
0.19±0.18 
(5) 
0.12±0.16 
(5) 
-0.13±0.09 
(5) 
-0.16±0.16 
(5) 
-
0.09±0.
16 (4) 
0.04±0.13 
(4) 
-0.09±0.16 
(5) 
0.01±0.16 
(5) 
-
0.25±0.1
3 (4) 
-0.53±0.17 
(4) 
0.27±0.1
7 (5) 
-0.32±0.17 
(4) 
K370A N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
I371A 
0.60±0.1
7 (5) 
0.52±0.21* 
(7) 
N.D. 
0.72±0.13 
(5) 
0.87±0.09* 
(6) 
N.D. 
0.78±0.18 
(4) 
1.00±0.12* 
(5) 
N.D. 
0.99±0.1
3* (5) 
N.D. 
1.06±0.1
9* (5) 
N.D. 
Y372A 
0.80±0.3
3 (4) 
-0.32±0.16 
(5) 
-
0.78±0.1
5* (5) 
0.29±0.12 
(4) 
-0.53±0.14 
(5) 
-
0.72±0.
15* (4) 
0.61±0.29 
(4) 
-
0.62±0.1
6* (5) 
-
0.95±0.2
5* (4) 
N.D. N.D. 
-
0.66±0.1
6* (5) 
N.D 
D373A 
0.69±0.2
3 (4) 
-0.06±0.16 
(5) 
-0.34±0.15 
(5) 
0.33±0.12 
(4) 
-0.18±0.16 
(5) 
-
0.06±0.
15 (4) 
0.96±0.31* 
(4) 
-0.56±0.19 
(5) 
-0.83±0.2* 
(5) 
-
0.27±0.1
2 (5) 
N.D. 
-
0.67±0.1
8* (5) 
N.D. 
Y374A 
0.15±0.0
9 (5) 
0.19±0.10 
(5) 
0.05±0.09 
(5) 
0.28±0.09 
(5) 
0.19±0.09 
(6) 
0.09±0.
09 (4) 
0.2±0.12 
(4) 
0.18±0.09 
(5) 
0.13±0.09 
(4) 
0.19±0.1
4 (4) 
-0.25±0.09 
(4) 
0.08±0.1
3 (5) 
-0.39±0.14 
(5) 
V375A 
0.33±0.1
5 (5) 
-0.27±0.10 
(5) 
-0.44±0.10 
(4) 
0.14±0.12 
(5) 
-0.23±0.09 
(6) 
-
0.41±0.
09 (5) 
0.69±0.28 
(4) 
0.08±0.16 
(5) 
-0.25±0.09 
(5) 
-
0.05±0.1
4 (5) 
-0.34±0.12 
(5) 
-
0.15±0.1
6 (5) 
-0.56±0.11 
(5) 
M376A 
-
0.08±0.
11 (5) 
-0.57±0.13 
(4) 
-0.60±0.09 
(4) 
0.10±0.10 
(5) 
-0.12±0.09 
(4) 
-
0.39±0.
09 (4) 
-0.07±0.15 
(4) 
-
0.69±0.1
3* (5) 
-
0.66±0.1
1* (5) 
-
0.12±0.1
5 (5) 
-
0.70±0.1
2* (5) 
-
0.53±0.1
6* (5) 
-
0.81±0.1
3* (5) 
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For each receptor mutant and ligand, concentration-response data for each pathway were fit with the Black 
and Leff operational model to derive an affinity-independent measure of efficacy (log(τ)).  These data were 
corrected for changes in cell surface expression from FACS to yield log(τc). All values are mean ± S.E.M. 
(independent “n” values are indicated within parentheses). For each ligand, significance of changes in log(τc) 
was determined by comparison of mutants to the WT receptor in a one-way analysis of variance followed by 
Dunnett’s post-test (p<0.05 represented by *). (N.D.) data were not able to be reliably determined. 
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Table 7. Interactions between either hCT or sCT and the CTR in MD simulations of bound 
peptide. 
CTR Residue Interaction hCT sCT 
I279 CTR H bonds / / 
CTR Contacts / / 
T280 CTR H bonds / / 
CTR Contacts / / 
R281 CTR H bonds / / 
CTR Contacts / / 
V283 CTR H bonds / / 
CTR Contacts / / 
Y284 CTR H bonds / / 
CTR Contacts / / 
F285 CTR H bonds / / 
CTR Contacts / / 
N286 CTR H bonds / / 
CTR Contacts / / 
D287 CTR H bonds / / 
CTR Contacts / / 
N288 CTR H bonds / / 
CTR Contacts / / 
C289 CTR H bonds / / 
CTR Contacts Q14 34.4% / 
W290 CTR H bonds /  H17 3.0% 
C1 2.5% (bb) CTR Contacts Q14 57.0% 
N17 54.7% 
T13 30.9% 
K18 25.8% 
S13 73.8% 
Q14 60.0% 
H17 59.0% 
G10 24.2% 
L291 CTR H bonds K18 2.3% (bs) / 
CTR Contacts Q 4 54.  
T 1 34.0  
/ 
S292 CTR H bonds / Q14 9.9% 
CTR Contacts / Q14 49.8% 
H17 28.0% V293 CTR H bonds / / 
CTR Contacts Q14 27.1% Q14 21.8% 
E294 CTR H bonds C1 8.7% (sb) / 
CTR Contacts / / 
T295 CTR H bonds / / 
CTR Contacts G2 22.5% / 
H296 CTR H bonds / / 
CTR Contacts / / 
L297 CTR H bonds / / 
CTR Contacts N3 26.2% / 
L298 CTR H bonds N3 9.5% (bs) / 
CTR Contacts N3 62.5% 
T6 27.8% 
N3 25.4% 
 Y299 CTR H bonds / / 
CTR Contacts N3 47.8% S2 29.5% 
I300 CTR H bonds / / 
CTR Contacts / / 
 
CTR Residue Interaction hCT sCT 
F356 CTR H bonds / S5 5.1% (bs) 
CTR Contacts M8 74.1% 
S5 54.0% 
L4 37.1% 
L9 26.1% 
L4 92.1% 
S5 77.4% 
V8 32.4% 
 
V357 CTR H bonds / / 
CTR Contacts  72.  
S5 41.7  
/ 
V358 CTR H bonds / / 
CTR Contacts / / 
F359 CTR H bonds / / 
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CTR Contacts M8 42.8% L4 60.6% 
P360 CTR H bonds / / 
CTR Contacts L4 67.2% 
M8 60.5% 
C7 41.8%% 
L4 89.6% 
C1 26.3% W361 CTR H bonds / / 
CTR Contacts C1 37.9% 
C7 34.3% 
L4 28.6% 
T11 25.9% 
L4 58.4% 
C1 43.2% 
C7 34.9% 
K11 31.8% 
V8 29.8% 
S2 26.8% 
R362 CTR H bonds / / 
CTR Contacts C1 0.3  K11 60.2% 
P363 CTR H bonds / / 
CTR Contacts / / 
S364 CTR H bonds / / 
CTR Contacts / / 
N365 CTR H bonds / / 
CTR Contacts / / 
K366 CTR H bonds / / 
CTR Contacts / / 
M367 CTR H bonds / / 
CTR Contacts / / 
L368 CTR H bonds / / 
CTR Contacts / / 
G369 CTR H bonds / / 
CTR Contacts / / 
K370 CTR H bonds / / 
CTR Contacts / / 
I371 CTR H bonds / / 
CTR Contacts / / 
Y372 CTR H bonds / / 
CTR Contacts M8 36.8% L4 45.4% 
D373 CTR H bonds C1 6.8% (sb) K11 13.0% 
CTR Contacts / K11 27.8% 
Y374 CTR H bonds / / 
CTR Contacts / / 
V375 CTR H bonds / / 
CTR Contacts / / 
M376 CTR H bonds / / 
CTR Contacts M8 77.2% L4 82.2% 
V8 49.7%  
Hydrogen bonds and generic contacts established between the CTR and both the human calcitonin (hCT) and 
salmon calcitonin (sCT), during 2 s of MD simulations (percentages are referred to the total number of 
frames). (sb): hydrogen bond involving a CTR side chain and the backbone of the hCT or sCT; (bs) hydrogen 
bond involving a CTR backbone atom and a hCT or sCT side chain. If not specified, the hydrogen bond refers to 
both the CTR and the hCT or sCT side chains. Only values higher than 2% for hydrogen bonds and 20% for 
generic contacts are reported.  
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